japanes
associ
infecti
diseas
jaid
japanes
societi
chemotherapi
jsc
announc
guid
use
antimicrobi
drug
guidelin
use
antimicrobi
drug
subsequ
jaid
jsc
guid
clinic
manag
infecti
diseas
publish
revis
guidelin
newli
prepar
concern
respiratori
infecti
diseas
japan
japanes
respiratori
societi
publish
guidelin
manag
communityacquir
pneumonia
hospitalacquir
pneumonia
respiratori
tract
infect
nurs
healthcareassoci
pneumonia
furthermor
japanes
societi
pediatr
pulmonolog
japanes
societi
pediatr
infecti
diseas
announc
guidelin
manag
respiratori
infecti
diseas
children
japan
intern
mani
guidelin
includ
establish
american
thorac
societi
infecti
diseas
societi
america
publish
variou
countri
thereaft
clinic
research
respiratori
infecti
diseas
advanc
lead
accumul
mani
outcom
regard
epidemiolog
clinic
diagnosi
treatment
howev
type
microorgan
caus
respiratori
infecti
diseas
increas
number
resist
bacteria
addit
condit
also
vari
caus
microorgan
recent
compromis
host
sever
statu
place
treatment
vari
outpati
clinic
icu
physician
respons
treatment
also
vari
practition
hospit
doctor
pulmonologist
emerg
physician
board
certifi
member
jaid
japanes
antimicrobi
chemotherapi
physician
larg
number
option
antimicrobi
drug
avail
includ
new
drug
therapeut
strategi
confus
hand
recent
entiti
pkpd
commonli
recogn
import
scientif
use
antimicrobi
drug
emphas
addit
japanes
societi
chemotherapi
establish
system
antimicrobi
chemotherapycertifi
physician
promot
widespread
adequ
use
antimicrobi
drug
base
two
societi
prepar
jaidjsc
guidelin
treatment
respiratori
infecti
diseas
specif
treatment
guidelin
present
may
contribut
improv
treatment
respons
respiratori
infecti
diseas
reduct
health
expenditur
prevent
resist
bacteria
guidelin
prepar
base
ebm
reflect
manag
respiratori
infecti
diseas
japan
cover
diseas
adult
children
prepar
guidelin
committe
establish
draft
publish
homepag
base
approv
board
director
two
societi
reviewbas
consensu
opinion
collect
two
societi
member
japan
guidelin
cover
respiratori
infecti
diseas
futur
advanc
research
content
guidelin
must
revis
howev
success
provid
treatment
guidelin
advanc
present
guidelin
prepar
clinician
understand
treatment
respiratori
infecti
diseas
manag
antimicrobi
drug
adequ
limit
treatment
individu
physician
affect
right
select
guidelin
may
commonli
appli
respiratori
infecti
diseas
managementresearcheduc
japan
improv
qualiti
respiratori
infecti
diseas
manag
prevent
increas
number
resist
bacteria
contribut
nation
health
hope
guidelin
util
larg
number
clinician
respiratori
infecti
diseas
manag
lastli
thank
committe
member
secretariat
staff
cooper
descript
recommend
grade
evid
level
definit
firstand
secondchoic
drug
precaut
articl
respect
administr
method
especi
dose
antimicrobi
drug
recommend
base
suffici
dose
consid
product
adopt
medic
institut
antibiogram
sever
underli
diseas
age
presenc
absenc
organ
disord
dose
increas
decreas
necessari
spectra
thirdgener
cephem
intraven
inject
ctx
ctrx
similar
ctx
excret
kidney
primarili
use
liver
dysfunct
present
ctrx
excret
bile
primarili
use
renal
dysfunct
present
quinolon
exhibit
antitubercular
action
patient
pulmonari
tuberculosi
exclud
use
list
antimicrobi
drug
abbrevi
dose
neonat
present
end
volum
communityacquir
pneumonia
empir
therapi
execut
summari
patient
bacteri
pneumonia
treat
primarili
highdos
penicillin
aii
elderli
patient
underli
lung
diseas
use
respiratori
quinolon
may
consid
posit
bii
case
atyp
pneumonia
macrolid
tetracyclin
first
choic
respiratori
quinolon
reserv
altern
drug
bii
may
use
depend
local
circumst
drug
resist
ciii
case
whether
pneumonia
atyp
pneumonia
dose
diagnos
comobin
highdos
penicillin
macrolid
tetracyclin
attempt
first
bii
respiratori
quinolon
reserv
altern
drug
bii
sever
case
requir
treatment
icu
macrolid
new
quinolon
use
aggress
combin
broad
spectrum
blactam
highdos
penicillin
begin
treatment
aii
explan
communityacquir
pneumonia
refer
hospitalacquir
pneumonia
develop
h
admiss
pneumonia
develop
healthi
adult
social
activ
medic
practicenursingassoci
pneumonia
sign
symptom
cough
sputum
thorac
pain
dyspnea
appear
diseas
acut
occur
system
symptom
fever
gener
malais
howev
symptom
mark
elderli
patient
furthermor
atyp
pneumonia
includ
mycoplasma
character
small
amount
sputum
differenti
tabl
concern
examin
gram
stain
cultur
sputum
use
identifi
caus
microorgan
select
subsequ
treatment
strategi
aii
kit
rapid
diagnosi
urin
nasal
swab
also
use
auxiliari
diagnosi
aii
blood
test
show
inflammatori
find
leukocytosi
increas
crp
level
facilit
certain
assess
diseas
thorac
imag
consolid
ground
glasslik
shadow
observ
ii
patient
immunosuppress
state
relat
underli
diseas
caus
microorgan
test
perform
consid
possibl
opportunist
infect
elderli
patient
aspir
pneumonia
frequent
observ
manag
disord
necessari
refer
section
aspir
pneumonia
page
presenc
renal
dysfunct
type
dose
antimicrobi
drug
must
care
select
aii
bacteri
pneumonia
differenti
atyp
pneumonia
accord
jr
guidelin
manag
communityacquir
pneumonia
adult
edit
committe
prepar
guidelin
regard
respiratori
infecti
diseas
japanes
respiratori
societi
tabl
although
legionella
pneumonia
routin
classifi
atyp
pneumonia
variou
type
atyp
pneumonia
includ
legionella
pneumonia
differenti
method
bacteri
pneumonia
outpati
treatment
bacteri
pneumonia
primarili
caus
sterptococcu
pneumonia
haemophilu
influenza
moraxella
catarrhali
ii
basic
type
pneumonia
treat
oral
administ
highdos
penicillin
aii
japan
macrolideresist
pneumonia
detect
case
therefor
macrolid
recommend
first
choic
differ
form
europ
unit
state
aii
outpati
treatment
blactamas
inhibitorcontain
penicillin
commonli
use
therapi
cvaampc
sbtpc
time
day
recommend
respect
efficaci
suppress
resist
bacteria
aii
howev
highdos
prescript
alway
accept
health
insur
system
japan
follow
prescript
exampl
also
consid
elderli
patient
underli
lung
diseas
copdold
pulmonari
tuberculosi
use
respiratori
quinolon
consid
posit
perspect
effect
penicillinresist
pneumococcu
tissu
transfer
bii
howev
mani
new
quinolon
also
antimicrobi
activ
mycobacterium
tuberculosi
therefor
presenc
absenc
activ
tuberculosi
must
strictli
check
administr
aii
hospit
treatment
hospit
treatment
inject
primarili
use
howev
basic
concept
drug
select
similar
outpati
clinic
consid
pneumonia
h
influenza
catarrhali
highdos
penicillin
cephem
effect
microorgan
select
aii
potent
treatment
requir
respiratori
quinolon
inject
use
bii
drug
recommend
outpati
treatment
first
choic
cvaampc
oral
mg
time
day
sbtpc
oral
mg
time
day
concern
cvaampc
sbtpc
mg
ampc
mg
abpc
approv
dosag
japan
combin
therapi
ampc
oral
prepar
also
consid
exampl
cvaampc
oral
mg
time
day
ampc
oral
mg
time
day
second
choic
lvfx
oral
mgonc
day
grnx
oral
mgonc
day
stfx
oral
time
day
mflx
oral
mgonc
day
tflx
oral
mgtwice
day
hospit
treatment
first
choic
sbtabpc
intraven
drip
time
day
ctx
intraven
drip
time
day
ctrx
intraven
drip
gonc
day
gtwice
day
second
choic
lvfx
intraven
drip
mgonc
day
b
atyp
pneumonia
outpati
treatment
atyp
pneumonia
primarili
caus
mycoplasma
pneumonia
chlamydophila
pneumonia
legionella
pneumophila
ii
oral
administr
macrolid
tetracyclin
first
choic
aii
suppress
resist
bacteria
respiratori
quinolon
reserv
altern
drug
bii
howev
recent
appear
macrolideresist
pneumonia
adult
rais
issu
japan
respiratori
quinolon
must
use
first
choic
depend
local
circumst
drug
resist
ciii
hospit
treatment
hospit
treatment
inject
primarili
use
howev
basic
concept
drug
select
similar
outpati
clinic
potent
treatment
requir
new
quinolon
inject
use
bii
drug
recommend
outpati
treatment
first
choic
azm
sustainedreleas
prepar
oral
gsingl
dose
cam
oral
mgtwice
day
mino
oral
mg
twice
day
second
choic
lvfx
oral
mgonc
day
grnx
oral
mgonc
day
stfx
oral
time
day
mflx
oral
mgonc
day
tabl
item
use
differenti
bacteri
atyp
pneumonia
year
age
minor
underli
diseas
stubborn
cough
poor
chest
auscultatori
find
sputum
identifi
aetiolog
agent
rapid
diagnosi
peripher
white
blood
cell
count
tabl
criteria
differenti
case
use
item
tflx
oral
mgtwice
day
hospit
treatment
azm
intraven
drip
mgonc
day
mino
intraven
drip
mgtwice
day
lvfx
intraven
drip
mgonc
day
cpfx
intraven
drip
mgtwice
day
pzfx
intraven
drip
mgtwice
day
c
case
whether
diseas
bacteri
pneumonia
atyp
pneumonia
unclear
outpati
treatment
case
combin
therapi
highdos
penicillin
macrolid
tetracyclin
select
first
choic
cover
bacteri
atyp
pneumonia
bii
respiratori
quinolon
cover
bacteri
atyp
pneumonia
conveni
reserv
altern
drug
perspect
suppress
resist
bacteria
bii
howev
elderli
patient
underli
lung
diseas
copdold
pulmonari
tuberculosi
use
respiratori
quinolon
consid
posit
perspect
effect
penicillinresist
pneumococcu
tissu
transfer
bii
recent
appear
macrolideresist
pneumonia
adult
rais
issu
respiratori
quinolon
may
use
first
choic
depend
local
circumst
drug
resist
ciii
hospit
treatment
hospit
treatment
inject
primarili
use
howev
basic
concept
drug
select
similar
outpati
clinic
potent
treatment
requir
new
quinolon
inject
use
bii
sever
case
requir
treatment
icu
sever
case
requir
treatment
icu
pneumonia
initi
consid
macrolid
new
quinolon
use
aggress
combin
broad
spectrum
blactam
highdos
penicillin
begin
treatment
primarili
cover
latent
atyp
bacteria
particular
l
pneumophila
cover
condit
may
becom
fatal
aii
particular
combin
therapi
macrolid
recommend
immunolog
aspect
suppress
excess
inflamm
relat
cytokin
cii
possibl
caus
microorgan
may
enter
bacteria
includ
esblproduc
bacteria
rule
carbapenem
inject
use
firstchoic
drug
patient
background
factor
esblproduc
bacteria
frequent
detect
bii
sensit
urinari
antigen
kit
pneumonia
legionella
spp
approxim
therefor
even
patient
neg
bacteria
initi
phase
possibl
pneumonia
relat
bacteria
rule
ii
drug
recommend
outpati
treatment
first
choic
cvaampc
oral
mg
time
day
sbtpc
oral
mg
time
day
concern
cvaampc
sbtpc
mg
ampc
mg
abpc
approv
dosag
japan
combin
therapi
ampc
oral
prepar
also
consid
exampl
cvaampc
oral
mg
time
day
ampc
oral
mg
time
day
one
follow
azm
sustainedreleas
prepar
oral
gsingl
dose
cam
oral
mgtwice
day
mino
oral
mgtwice
day
second
choic
lvfx
oral
mgonc
day
grnx
oral
mgonc
day
stfx
oral
time
day
mflx
oral
mgonc
day
tflx
oral
mgtwice
day
hospit
treatment
first
choic
sbtabpc
intraven
drip
time
day
ctx
intraven
drip
time
day
ctrx
intraven
drip
gonc
day
gtwice
day
one
follow
azm
intraven
drip
mgonc
day
mino
intraven
drip
mgtwice
day
cam
oral
mgtwice
day
second
choic
lvfx
intraven
drip
mgonc
day
pzfx
intraven
drip
mgtwice
day
sever
case
requir
treatment
icu
tazpipc
intraven
drip
time
day
ipmc
intraven
drip
time
day
mepm
intraven
drip
time
day
bipm
intraven
drip
time
day
drpm
intraven
drip
time
day
one
follow
azm
intraven
drip
mgonc
day
lvfx
intraven
drip
mgonc
day
cpfx
intraven
drip
mgtwice
day
pzfx
intraven
drip
mgtwice
day
mino
intraven
drip
mgtwice
day
execut
summari
caus
microorgan
identifi
base
result
microbi
examin
goodqual
sputum
blood
cultur
urinari
antigen
pneumonia
l
pneumophila
test
drug
suscept
test
caus
agent
definit
therapi
perform
possibl
biii
place
treatment
drug
select
accord
sever
diseas
aii
antimicrobi
drug
select
refer
suscept
isol
bacteria
antimicrobi
drug
drugsuscept
tendenc
area
data
avail
aii
administr
period
antimicrobi
drug
determin
accord
improv
symptom
laboratori
data
target
day
biii
patient
infect
l
pneumophila
c
pneumonia
optim
administr
period
day
biv
streptococcu
pneumonia
clinic
laboratori
standard
institut
clsi
establish
higher
criteria
breakpoint
penicillin
suscept
administr
parenter
antimicrobi
drug
pneumonia
infect
mening
base
follow
find
patient
sever
pneumonia
due
pneumonia
low
pcg
suscept
mic
mgml
show
differ
respons
pcg
outcom
ii
treatment
pneumococc
pneumonia
dose
penicillin
increas
japan
pneumonia
isol
macrolid
resist
respiratori
quinolon
potent
antipneumococc
activ
iii
clinic
effect
quinolon
similar
highdos
ampc
ii
japan
quinoloneresist
pneumonia
detect
isol
quinolon
resist
may
readili
induc
point
mutat
dna
gyras
topoisomeras
gene
quinolon
must
use
adequ
aiii
b
haemophilu
influenza
abpcresist
mechan
h
influenza
involv
blactamas
product
andor
pbp
mutat
previous
blactamas
product
primarili
involv
recent
pbp
mutationmedi
blactamaseneg
abpcresist
blnar
strain
increasingli
detect
abpcresist
strain
blactamas
product
pbp
mutat
classifi
blactamaseposit
cvaabpcresist
blpacr
strain
accord
nation
survey
japan
h
influenza
strain
blnar
blactamaseproduc
strain
respect
blnar
strain
also
resist
firstand
secondgener
cephem
pipc
exhibit
antimicrobi
activ
blnar
strain
howev
ineffect
blpacr
strain
c
klebsiella
spp
escherichia
coli
proteu
spp
proport
extend
spectrum
blactamas
esbl
produc
bacteria
slightli
increas
among
isol
respiratori
sampl
accord
nation
survey
japan
esblproduc
bacteria
account
respiratori
samplederiv
klebsiella
spp
strain
esblproduc
strain
simultan
resist
quinolon
antimicrobi
select
accord
drug
suscept
isol
bacteria
japan
carbapenemaseproduc
strain
extrem
rare
mycoplasma
pneumonia
field
pediatr
detect
rate
macrolideresist
pneumonia
markedli
increas
adult
macrolideresist
pneumonia
also
increas
tetracyclin
exhibit
potent
clinic
effect
macrolideresist
pneumonia
respiratori
quinolon
good
activ
pneumonia
e
legionella
spp
note
pneumonia
relat
legionella
spp
l
pneumophila
diagnos
use
legionella
urinari
antigen
test
neither
blactam
aminoglycosid
antimicrobi
activ
legionella
spp
prolifer
within
host
cell
clinic
ineffect
quinolon
macrolid
tetracyclin
confirm
exhibit
clinic
effect
legionella
spp
previous
em
first
choic
infect
mani
recent
studi
show
clinic
efficaci
lvfx
azm
rfp
effect
combin
em
combin
em
rfp
use
studi
suggest
effect
combin
therapi
lvfx
macrolid
ciii
although
mark
differ
antimicrobi
drug
suscept
among
legionella
spp
clinic
review
verifi
limit
f
chlamydophila
pneumonia
studi
support
clinic
effect
antimicrobi
drug
c
pneumonia
pulmonari
infect
tetracyclin
macrolid
quinolon
may
effect
drug
recommend
primarili
base
result
basic
studi
g
staphylococcu
aureu
respect
staphylococcu
aureu
japan
increas
number
methicillinresist
strain
even
patient
communityacquir
pneumonia
particular
recent
municipalonsettyp
mrsa
camrsa
pantonvalentineleucocidin
pvl
detect
japan
rais
issu
case
mssa
infect
bacteremia
clinic
effect
cez
superior
vcm
suscept
mrsa
oral
antimicrobi
drug
differ
among
isol
drug
select
accord
drug
suscept
result
h
streptococcu
spp
among
variou
type
streptococcu
streptococcu
anginosu
group
frequent
detect
character
strong
abscessform
featur
streptococcu
pyogen
streptococcu
agalactia
may
also
caus
pneumonia
former
may
lead
seriou
pulmonari
infect
v
penicillin
resist
macrolid
resist
observ
low
frequenc
antistreptococcu
activ
quinolon
vari
among
quinolon
grnx
mflx
stfx
rel
potent
antimicrobi
activ
moraxella
catarrhali
number
blactamaseproduc
strain
increas
sinc
current
strain
produc
blactamas
blactamas
produc
catarrhali
decompos
penicillin
japan
macrolideor
quinoloneresist
report
j
anaerob
anaerob
caus
pneumonia
exist
oral
caviti
peptostreptococcu
spp
prevotella
spp
fusobacterium
spp
involv
mix
infect
microaerophil
streptococci
often
observ
mani
case
infect
anaerob
may
associ
aspir
oral
anaerob
prevotella
spp
fusobacterium
spp
porphyromona
spp
suscept
combin
drug
consist
penicillin
blactamas
inhibitor
cldm
mnz
k
pseudomona
aeruginosa
patient
chronic
respiratori
tract
infect
pseudomona
aeruginosa
colon
airway
may
caus
communityacquir
pneumonia
suscept
p
aeruginosa
antimicrobi
drug
differ
among
clinic
isol
drug
select
accord
drug
suscept
result
drug
recommend
drug
suscept
clinic
isol
classifi
accord
clsi
criteria
establish
prescript
recommend
articl
antimicrobi
approv
specif
diseas
specif
caus
agent
japanes
ministri
health
welfar
approv
base
result
clinic
studi
good
clinic
practic
gener
rule
recommend
section
refer
aii
howev
recent
trend
drug
suscept
also
consid
recent
drug
suscept
result
nationwid
studi
japan
refer
recommend
without
approv
japanes
ministri
grade
evid
level
suscept
identifi
caus
microorgan
clarifi
treatment
respons
evalu
whether
deescal
possibl
review
aii
explan
definit
hospitalacquir
pneumonia
defin
pneumonia
newli
develop
h
admiss
mani
case
treatment
difficult
due
unfavor
patient
condit
presenc
underli
diseas
immun
capac
gener
condit
laboratori
find
patient
meet
item
fever
abnorm
leukocyt
count
purul
secret
addit
appear
abnorm
shadow
chest
diagnos
hospitalacquir
pneumonia
ventilatorassoci
pneumonia
vap
vap
refer
pneumonia
newli
develop
h
endotrach
intubationventil
initi
onset
within
day
endotrach
intub
classifi
earlytyp
subsequ
onset
latetyp
hospitalacquir
pneumonia
vap
sever
type
hospitalacquir
pneumonia
vap
includ
immunodefici
exampl
neutropenia
anticanc
therapi
cellmedi
immunodefici
relat
administr
steroid
immunosuppress
drug
aspir
pneumonia
includ
latent
aspir
refer
section
aspir
pneumonia
page
appropri
manag
select
antimicrobi
drug
accord
individu
condit
necessari
respect
microorgan
expect
refer
section
hospitalacquir
pneumonia
empir
therapi
case
gram
stain
avail
p
drug
recommend
case
risk
resist
bacteria
antimicrobi
drug
select
target
streptococcu
pneumonia
h
influenza
klebsiella
spp
caus
microorgan
biii
although
difficult
estimateidentifi
caus
microorgan
use
sputum
sampl
bacteria
isolatedcultur
goodqual
sputum
may
caus
microorgan
resist
bacteria
mrsa
p
aeruginosa
detect
sputum
cultur
deterior
clinic
symptom
initi
drug
continu
biii
patient
aspir
episod
clear
oral
hygien
maintain
conscious
disord
drug
antianaerob
activ
select
consid
involv
anaerob
biii
adequ
antimicrobi
drug
administ
treatment
period
may
day
exclud
mrsa
p
aeruginosa
bii
first
choic
sbtabpc
intraven
drip
time
day
ctx
intraven
drip
time
day
ctrx
intraven
drip
gonc
day
gtwice
day
involv
anaerob
suspect
sbtabpc
select
second
choic
lvfx
intraven
drip
mgonc
day
antimicrobi
activ
anaerob
weak
monotherapi
drug
avoid
patient
aspir
pneumonia
b
case
risk
multidrugresist
bacteria
tabl
cover
multidrugresist
bacteria
includ
p
aeruginosa
broadspectrum
antimicrobi
drug
antip
aeruginosa
activ
select
aiii
consid
frequenc
esbl
institut
carbapenem
consid
even
enter
bacteria
includ
klebsiella
spp
escherichia
coli
suspect
biv
p
aeruginosa
isol
goodqual
sputum
cultur
treatment
option
deescal
drug
case
risk
resist
bacteria
aii
aspir
suspect
involv
gramposit
bacteria
suggest
combin
therapi
cldm
must
consid
biv
risk
mrsa
carrier
tabl
combin
therapi
antimrsa
drug
also
consid
mean
administr
period
antimicrobi
drug
respect
caus
bacteria
patient
improv
approxim
day
howev
resist
bacteria
p
aeruginosa
mrsa
approxim
day
bii
appropri
antimicrobi
drug
administ
clarifi
caus
bacteria
treatment
period
approxim
day
recommend
bii
first
choic
tazpipc
intraven
drip
time
day
ipmc
intraven
drip
time
day
time
day
mepm
intraven
drip
time
day
drpm
intraven
drip
time
day
bipm
intraven
drip
time
day
second
choic
cfpm
intraven
drip
time
day
cpfx
intraven
drip
mgtwice
day
pzfx
intraven
drip
mgtwice
day
involv
anaerob
suspect
one
follow
option
combin
one
regimen
cldm
intraven
drip
time
day
sbtabpc
intraven
drip
time
day
c
sever
case
one
follow
option
must
combin
one
regimen
case
risk
multidrugresist
bacteria
compar
result
patient
undergo
appropri
inappropri
treatment
prognosi
latter
significantli
poorer
bii
howev
studi
report
prognosi
group
complianc
recommend
drug
select
significantli
poorer
noncompli
group
patient
infect
drugresist
bacteria
icu
suspect
even
among
etiolog
bacteriolog
investig
bii
therefor
must
consid
even
resist
bacteria
etiolog
involv
administr
appropri
antimicrobi
drug
cover
alway
improv
prognosi
tazpipc
intraven
drip
time
day
ipmc
intraven
drip
time
day
time
day
mepm
intraven
drip
time
day
drpm
intraven
drip
time
day
bipm
intraven
drip
time
day
one
follow
option
combin
one
regimen
estim
base
result
clinic
microbiolog
cultur
cmc
gram
stain
cultur
lower
airway
sampl
immedi
start
treatment
base
bacteria
isol
activ
surveil
cultur
asc
conduct
strategi
prevent
control
infect
prior
onset
microorgan
caus
pneumonia
colon
lower
airway
estim
base
presenc
absenc
neutrophil
phagocytosi
exclud
patient
neutropenia
function
impair
neutrophil
bii
explan
gram
stain
diagnost
accuraci
hospitalacquir
pneumonia
improv
confirm
neutrophil
bacteri
cell
use
gram
stain
airway
sampl
observ
also
confirm
increas
likelihood
ratio
hospitalacquir
pneumonia
patient
clinic
pulmonari
infect
score
cpi
point
higher
bacteria
isol
lower
airway
inpati
common
colon
mani
case
gram
stain
also
use
discern
colon
infect
evalu
presenc
absenc
neutrophil
phagocytosi
therefor
desir
combin
bacteri
cultur
gram
stain
antimicrobialdrug
select
base
gram
stain
find
lead
appropri
empir
therapi
twothird
patient
hospitalacquir
pneumonia
continu
definit
therapi
mani
case
bacteri
cell
gram
stain
lower
airway
sampl
antimicrobi
regimen
chang
within
past
h
unlik
focu
infectioninflamm
within
lung
lower
airway
case
possibl
pneumonia
mimic
pleural
effus
atelectasi
pulmonari
edema
suggest
lung
field
opac
still
remain
chest
xray
infecti
focu
discontinu
antimicrobi
drug
may
warrant
studi
report
cultur
result
asc
perform
strategi
routin
infect
control
measur
prior
develop
nosocomi
pneumonia
accur
predict
caus
pathogen
case
therefor
necessari
submit
airway
sampl
clinic
microbiolog
cultur
cmc
immedi
start
presumpt
treatment
caus
microorgan
origin
microorgan
caus
hospitalacquir
pneumonia
deriv
oropharynx
airway
includ
nasal
caviti
nasal
sinu
digest
tract
environ
gastrointestin
tractderiv
caus
microorgan
enter
bacteria
primarili
klebsiella
spp
e
coli
other
proteu
spp
enterobact
spp
serratia
spp
morganella
spp
citrobact
spp
deriv
upper
airway
includ
pneumonia
h
influenza
moraxella
catarrhali
aureu
name
methicillin
sensit
strain
oral
anaerob
deriv
environ
includ
methicillinsensit
aureu
pseudomona
spp
acinetobact
spp
stenotrophomona
spp
bacteria
deriv
airway
gastrointestin
tract
basic
exert
strong
virul
airway
consid
core
pathogen
group
hospitalacquir
pneumonia
potenti
develop
airway
inflammatori
respons
gener
believ
stronger
caus
environment
pathogen
tabl
risk
factor
multidrugresist
bacteria
previou
use
antimicrobi
drug
within
day
interv
day
admiss
admiss
areahospit
resist
bacteria
frequent
immunosuppress
state
treatment
tabl
risk
factor
carri
mrsa
condit
antimrsa
drug
therapi
consid
includ
gram
stain
mrsa
p
diplococcu
consist
pair
two
cocci
gpdc
gramposit
diplococci
pneumonia
initi
suspect
enterococcu
also
gpdc
microscop
appear
basic
consid
nonpulmonari
pathogen
case
previou
treatment
antimicrobi
drug
risk
penicillinresist
pneumococcu
pcg
intraven
drip
time
day
abpc
intraven
drip
time
day
case
previou
treatment
antimicrobi
drug
risk
prsp
present
ctrx
intraven
drip
gtwice
day
gonc
day
ctx
intraven
drip
time
day
lvfx
intraven
drip
mgonc
day
vcm
intraven
drip
gtwice
day
tdm
conduct
trough
mgml
gramposit
coccu
either
short
long
chain
gpc
chain
aor
bhemolyt
streptococci
indic
pcg
intraven
drip
unit
time
day
abpc
intraven
drip
time
day
gramposit
bacillu
rodlik
morpholog
gpr
gramposit
rod
corynebacterium
spp
may
indic
vcm
intraven
drip
gtwice
day
tdm
conduct
trough
mgml
c
gramneg
bacteria
execut
summari
gramneg
bacteria
observ
h
influenza
catarrhali
enterobacteriacea
p
aeruginosa
acinetobact
spp
stenotrophomona
spp
may
indic
bii
difficult
estim
type
bacteria
base
morpholog
gram
stain
comparison
gramposit
bacteria
gramneg
bacteria
frequent
detect
caus
microorgan
includ
enter
bacteria
p
aeruginosa
encourag
import
recogn
basic
antimicrobi
drug
suscept
pattern
type
group
bacteria
make
sure
empir
antimicrobi
therapi
appropri
tabl
drug
recommend
case
earlyonset
hospitalacquir
pneumonia
previou
administr
antimicrobi
drug
risk
resist
bacteria
aerorespiratori
pathogen
h
influenza
catarrhali
enter
bacteria
klebsiella
spp
indic
sbtabpc
intraven
drip
time
day
ctrx
intraven
drip
gtwice
day
gonc
day
ctx
intraven
drip
time
day
lvfx
intraven
drip
mgonc
day
case
lateonset
hospitalacquir
pneumonia
ventilatorassoci
pneumonia
risk
resist
bacteria
high
antimicrobi
drug
antipseudomon
activ
target
nonglucosefer
gramneg
rod
administ
treat
polymicrobi
infect
administr
antimicrobi
drug
activ
oblig
anaerob
alway
necessari
nonsever
case
administr
antimicrobi
agent
antimrsa
activ
may
withheld
initi
phase
even
staphylococcuslik
bacteri
cell
observ
explan
sever
type
bacteria
differ
gram
stain
morpholog
observ
condit
commonli
interpret
aspir
pneumonia
suggest
involv
anaerob
howev
number
hospitalacquir
pneumonia
includ
vap
caus
anaerob
report
rel
smaller
gener
anticip
polymicrobi
infect
alway
requir
prompt
antimicrobi
therapi
cover
anaerob
even
though
aspir
pneumonia
suspect
sbtabpc
frequent
prescrib
assum
anaerob
infect
actual
work
good
mani
occas
acknowledg
sbtabpc
exert
good
antimicrobi
activ
sole
anaerob
also
aeroenter
pathogen
pneumonia
streptococcu
pneumonia
oral
streptococci
h
influenza
catarrhali
klebsiella
pneumonia
inpati
often
expos
gramneg
bacteria
resid
hospit
environ
furthermor
mani
opportun
undergo
antimicrobi
drug
therapi
affect
indigen
microflora
reason
gramneg
bacillu
enter
bacteria
p
aeruginosa
frequent
colon
within
oropharyng
region
elderli
patient
longterm
bedbound
patient
mani
need
airway
suction
tracheostomi
may
serv
portal
entri
environment
pathogen
oropharyng
microflora
primarili
consist
gramneg
bacteria
aspir
airway
surgeri
requir
sedat
anesthesia
endoscop
examin
briefli
anaerob
may
occasion
pathoen
polymicrobi
infect
seen
gram
stain
patient
suspect
aspir
pneumonia
pneumonia
h
influenza
aureu
klebsiella
spp
p
aeruginosa
acinetobact
spp
commonli
involv
mani
case
similar
microorgan
thought
major
pathogen
hospitalacquir
pneumonia
contrast
communityonset
aspir
pneumonia
repres
lung
abscess
anaerob
primarili
involv
anaerob
involv
hospitalacquir
pneumonia
includ
facult
anaerob
ahemolyt
streptococci
oral
caviti
oblig
anaerob
oral
oblig
anaerob
includ
gramposit
coccu
peptostreptococcu
sp
gramneg
coccu
veillonella
sp
gramneg
bacillu
oral
pigment
bacteroid
bacteroid
melaninogenicu
prevotella
sp
porphyromona
sp
fusobacterium
sp
mani
type
bacteria
suscept
blactam
contain
blactamas
inhibitor
new
quinolon
macrolid
tetracyclin
therefor
patient
hospitalacquir
pneumonia
may
basic
treat
standard
empir
therapi
hospitalacquir
pneumonia
even
aspir
pneumonia
relat
sever
type
bacteria
suspect
drug
recommend
case
necessari
consid
involv
multidrugresist
bacteria
earli
hospitalacquir
pneumonia
involv
oral
streptococcu
oral
anaerob
pneumonia
h
influenza
enter
bacteria
consid
sbtabpc
intraven
drip
time
day
ctrx
intraven
drip
gonc
day
gtwice
day
ctx
intraven
drip
time
day
lvfx
intraven
drip
mgonc
day
lateonset
hospitalacquir
pneumonia
case
risk
multidrugresist
bacteria
addit
pathogen
involv
nonglucosefer
gram
neg
bacteria
esblproduc
enter
bacteria
must
consid
cfpm
intraven
drip
time
day
czop
intraven
drip
time
day
tazpipc
intraven
drip
time
day
tabl
basic
suscept
variou
pathogen
group
antimicrobi
drug
explan
drug
suscept
test
conduct
reason
identif
caus
microorgan
antimicrobi
drug
select
refer
suscept
pattern
local
sensit
identifi
bacteria
institut
local
sensit
obtain
drug
select
base
basic
suscept
variou
pathogen
antimicrobi
drug
tabl
treatment
hospitalacquir
pneumonia
durat
antimicrobi
therapi
gener
tend
longer
requir
follow
reason
opac
chest
xray
often
remain
reason
pneumonia
even
start
antimicrobi
drug
treatment
may
larg
number
latent
nonpneumonia
noninfectiousdiseas
factor
may
caus
increas
bodi
temperatur
crp
level
inpati
howev
appropri
antimicrobi
drug
treatment
perform
possibl
complet
treatment
week
strain
enterobact
spp
serratia
spp
citrobact
spp
morganella
spp
tabl
gnr
b
express
intrins
antimicrobialdrugresist
gene
encod
chromosom
gene
induc
antimicrobi
drug
treatment
phenomenon
basic
rare
seen
e
coli
klebsiella
spp
h
influenza
catarrhali
tabl
gnr
tabl
therefor
adequ
chosen
treatment
paramet
improv
antimicrobi
treatment
could
complet
care
follow
patient
condit
although
use
recogn
pathogen
abbrevi
space
serratia
pseudomona
acinetobact
citrobact
enterobact
repres
microorgan
group
caus
hospitalacquir
pneumonia
space
group
essenti
common
colon
therefor
import
bear
mind
antimicrobi
drug
alway
indic
upon
isol
space
avoid
select
antimicrobi
resist
bacteria
relat
unnecessari
longterm
antimicrobi
therapi
lzd
select
ai
therapeut
efficaci
lzd
similar
glycopeptid
penetr
lzd
alveolar
epitheliumlin
fluid
intraalveolar
sputum
favor
therefor
use
lzd
encourag
case
restrict
sputum
expector
vap
bii
exclus
use
singl
drug
may
acceler
acquisit
resist
agent
ci
dap
inactiv
pulmonari
surfact
use
avoid
mrsa
pneumonia
glycopeptid
select
firstlin
drug
pneumonia
caus
corynebacterium
sp
aii
explan
signific
differ
therapeut
efficaci
mrsa
pneumonia
glycopeptid
lzd
sever
studi
report
overal
clinic
efficaci
lzd
includ
incid
side
effect
superior
vcm
patient
hospitalacquir
pneumonia
caus
mrsa
howev
sinc
dose
vcm
studi
consid
suboptim
studi
need
investig
recommend
mrsa
suscept
cldm
mino
suscept
test
lzd
protein
synthesi
inhibitor
administ
given
possibl
involv
pantonvalentin
leukocidin
prompt
improv
achiev
intraven
drip
lzd
mg
patient
condit
critic
switch
intraven
administr
oral
prepar
lzd
show
high
bioavail
encourag
dap
inactiv
pulmonari
surfact
use
treat
mrsa
pneumonia
may
appli
treatment
septic
pulmonari
embol
drug
recommend
mrsa
first
choic
vcm
intraven
drip
gtwice
day
teic
intraven
drip
mg
first
day
twice
day
load
mgonc
day
day
tdm
conduct
trough
level
vcm
teic
rang
mgml
lzd
intraven
drip
oral
administr
mg
twice
day
second
choic
abk
intraven
drip
mgonc
day
trough
level
establish
mgml
use
tdm
st
combin
drug
smx
mgtmp
mg
oral
administr
tabletstwic
day
intraven
drip
mgtwice
day
cldm
intraven
drip
time
day
result
drug
suscept
test
must
confirm
nonextendedspectrum
blactamas
esbl
produc
bacteria
hospit
treatment
e
coli
klebsiella
spp
proteu
mirabili
esblproduc
bacteria
refer
section
communityacquir
pneumonia
definit
therapi
klebsiella
spp
esblproduc
bacteria
hospit
treatment
p
enterobact
spp
serratia
spp
citrobact
spp
morganella
spp
proteu
vulgari
thirdgener
cephem
quinolon
administ
aii
ctrx
intraven
drip
gonc
day
gtwice
day
ctx
intraven
drip
time
day
lvfx
intraven
drip
mgonc
day
cpfx
intraven
drip
mgtwice
day
pzfx
intraven
drip
mgtwice
day
strain
estim
constantli
express
cephalosporinas
highli
resist
blactamas
inhibitorcontain
blactam
oxyimino
gener
cephalosporin
cephamycin
plasmid
gene
antimicrobi
drug
suscept
test
fourthgener
cephem
carbapenem
administ
cfpm
intraven
drip
time
day
czop
intraven
drip
time
day
mepm
intraven
drip
time
day
drpm
intraven
drip
time
day
p
aeruginosa
antipseudomon
penicillin
thirdgener
later
cephem
carbapenem
new
quinolon
administ
refer
section
communityacquir
pneumonia
definit
therapi
h
influenza
abpcsuscept
h
influenza
blactamaseproduc
h
influenza
blactamaseneg
ampicillinresist
blnar
h
influenza
blactamaseposit
amoxicillin
clavulanateresist
blpacr
p
explan
accord
investig
enter
bacteria
classifi
type
sensit
gramneg
rod
e
coli
klebsiella
pneumonia
p
mirabili
suscept
firstgener
cephalosporin
resist
gramneg
rod
enterobact
spp
serratia
spp
citrobact
spp
show
intrins
induc
resist
thirdgener
cephalosporin
chromosom
ampc
gene
addit
number
extend
spectrum
blactamas
esbl
produc
strain
e
coli
klebsiella
proteu
sp
resist
cephalosporin
increas
among
resist
gnr
enterobact
spp
strain
constantli
produc
ampctyp
blactamas
cephalosporinas
plasmid
type
must
also
consid
concern
nonfer
bacteria
intrins
suscept
antimicrobi
agent
differ
among
p
aeruginosa
stenotrophomona
spp
acinetobact
spp
studi
indic
patient
p
aeruginosa
pneumonia
monotherapi
new
quinolon
might
show
unfavor
bacteriaerad
effect
lead
recrudesc
patient
combin
therapi
blactam
pipc
caz
cfpm
carbapenem
antipseudomon
activ
aminoglycosid
new
quinolon
may
consid
strain
stenotrophomona
spp
suscept
mino
st
combin
drug
catarrhali
acinetobact
spp
frequent
type
gramneg
coccu
detect
patient
earli
late
hospitalacquir
pneumonia
respect
mani
strain
former
produc
blactamas
latter
gnr
exist
hospit
environ
may
resist
mani
antimicrobi
drug
howev
japan
multidrug
resist
type
bacteria
wide
distribut
carbapenem
new
quinolon
select
howev
vast
major
acinetobacct
strain
suscept
sbtabpc
particular
sbt
antimicrobi
activ
type
bacteria
suscept
sbtabpc
routin
confirm
primari
test
drug
antimicrobi
suscept
type
bacteria
drug
appropri
routin
examin
panel
sbtabpc
caz
ipmc
mepm
gm
tob
lvfx
cpfx
pansensit
strain
h
influenza
blactamas
bl
neg
abpcsensit
blna
strain
howev
variou
resist
pattern
blproduc
abpcresist
blpar
blneg
abpcresist
blnar
blproduc
ampccvaresist
blpacr
strain
blna
strain
treat
abpc
sbtabpc
therapi
requir
control
blpar
strain
administr
ctrx
new
quinolon
necessari
blnar
blpacr
randomizedcontrol
trial
multivari
analysi
shown
factor
favor
bacteriolog
effect
includ
absenc
p
aeruginosarel
pneumonia
higher
bodi
weight
low
apach
ii
score
sever
cpfx
therapi
condit
suggest
use
new
quinolon
includ
allergi
blactam
presenc
concern
nephropathi
aminoglycosid
combin
blactam
necess
cover
oblig
intracellular
pathogen
situat
switch
oral
prepar
indic
vitro
studi
indic
alveolar
epitheli
line
fluid
elf
concentr
lvfx
reach
high
serum
concentr
furthermor
prospect
openlabel
studi
report
switch
intraven
drip
oral
administr
decreas
elf
concentr
within
rang
mani
pathogen
deem
sensit
base
cumul
data
minimum
inhibitori
concentr
caus
microorgan
execut
summari
nurs
healthcareassoci
pneumonia
nhcap
categori
independ
defin
japan
base
medic
circumst
attend
physician
propos
treatment
categori
group
evalu
treatment
necessari
import
item
base
patient
hisher
famili
fig
risk
factor
resist
bacteria
categor
two
item
initi
treatment
option
recommend
assum
target
caus
microorgan
civ
patient
gener
condit
unfavor
due
complic
terminalstag
patient
initi
treatment
option
recommend
consid
side
effect
perspect
innoc
properti
civ
group
intens
care
requir
combin
therapi
broadspectrum
involv
resist
bacteria
legionella
potent
antimicrobi
drug
recommend
bi
explan
japanes
respiratori
societi
issu
guidelin
manag
nurs
healthcareassoci
pneumonia
nhcap
consid
medic
circumst
japan
refer
entiti
healthcareassoci
pneumonia
hcap
propos
unti
state
definit
nhcap
shown
tabl
committe
object
entiti
select
drug
explain
base
evid
avoid
duplic
guidelin
mortal
rate
frequenc
resist
bacteria
patient
nhcap
intermedi
communityacquir
pneumonia
cap
hospitalacquir
pneumonia
hap
howev
nhcap
may
primarili
regard
similar
geriatr
pneumonia
fact
rate
resist
bacteria
isol
increas
sever
even
pneumonia
sever
host
activ
daili
live
adl
underli
diseaseimmunodefici
reduc
prognosi
mani
case
type
pneumonia
develop
varieti
uneven
popul
difficult
simpli
determin
sever
classif
therefor
consid
variou
condit
entiti
treatment
categori
involv
ethic
aspect
geriatr
care
introduc
base
evalu
attend
physician
know
patient
well
fig
frequent
basic
condit
concomit
diseas
nhcap
japan
includ
advanc
age
central
nervou
diseas
aspir
reduct
adl
tubal
feed
factor
aspir
pneumonia
risk
factor
hcap
japan
may
overlap
aspir
pneumonia
hand
nhcap
patient
mrsa
p
aeruginosa
anaerob
frequent
isol
comparison
cap
patient
necessari
switch
therapeut
strategi
consid
caus
microorgan
refer
next
section
aspir
pneumonia
p
type
frequenc
caus
microorgan
concern
caus
microorgan
nhcap
patient
resist
bacteria
frequent
detect
differ
cap
patient
howev
respect
microorgan
caus
hcap
distribut
frequenc
streptococcu
pneumonia
h
influenza
frequent
isol
cap
patient
well
mrsa
p
aeruginosa
gramneg
bacillu
frequent
detect
hap
patient
differ
among
countri
area
institut
due
varieti
iii
concern
caus
microorgan
studi
report
mark
differ
nhcap
cap
hand
studi
unit
state
indic
aureu
frequent
detect
anoth
studi
itali
rapid
age
societi
advanc
describ
japan
report
aspir
pneumonia
h
influenza
aureu
gramneg
bacillu
frequent
patient
cap
result
rate
resist
bacteria
increas
inappropri
antimicrobi
drug
select
high
proport
patient
addit
mortal
rate
higher
cap
patient
suggest
associ
two
factor
repres
caus
microorgan
respect
presenc
absenc
risk
factor
resist
bacteria
present
tabl
resist
bacteria
target
cap
patient
isol
approxim
howev
valu
lower
hap
patient
current
statu
japan
iii
howev
must
consid
patient
isol
bacteria
unclear
account
approxim
involv
aspir
background
factor
addit
bacteria
commonli
isol
cap
patient
frequenc
enter
bacteria
anaerob
increas
rule
antimicrobi
drug
therapi
risk
factor
resist
bacteria
nhcap
patient
includ
previou
use
antimicrobi
drug
day
within
day
tubal
feed
risk
factor
involv
drugresist
pathogen
antibiot
therapi
preced
day
current
tube
feed
patient
assum
risk
involv
drugresist
pathogen
howev
past
medic
histori
indic
isol
mrsa
patient
assum
risk
involv
mrsa
inappropri
aspir
pneumonia
suspect
insuffici
activ
anaerob
bacteria
insuffici
activ
anaerob
bacteria
use
treat
suspect
aspir
pneumonia
use
combin
antibiot
activ
anaerob
bacteria
eg
mnz
cldm
sbtabpc
definit
nhcap
pneumonia
diagnos
resid
extend
care
facil
nurs
home
pneumonia
diagnos
person
discharg
hospit
within
preced
day
pneumonia
diagnos
elderli
disabl
person
receiv
nurs
care
pneumonia
diagnos
person
receiv
regular
endovascular
treatment
outpati
dialysi
antibiot
therapi
chemotherapi
immunosuppress
therapi
standard
nurs
care
patient
whose
perform
statu
ps
capabl
limit
selfcar
confin
bed
chair
wake
hour
item
incud
patient
psychiatr
ward
isol
made
favor
daili
life
activ
without
histori
antimicrobi
drug
therapi
anoth
studi
indic
tubal
feed
independ
risk
factor
infect
p
aeruginosa
odd
ratio
ii
reason
treatment
categori
c
establish
guidelin
briefli
patient
meet
two
item
regard
risk
factor
resist
bacteria
assign
group
b
patient
meet
item
mrsa
previous
isol
assign
group
c
respect
drug
recommend
separ
establish
patient
outpati
treatment
consid
appropri
assign
group
attend
physician
consid
ventil
icu
manag
necessari
group
drug
recommend
ad
treatment
categori
algorithm
fig
prepar
concern
hcap
treatment
europ
unit
state
gap
drug
use
clinic
practic
recommend
guidelin
ii
therefor
treatment
categorybas
empir
therapi
japan
may
accept
clinic
practic
futur
investig
necessari
evid
regard
administr
period
antimicrobi
drug
administr
period
day
routin
adopt
highest
percentag
patient
appropri
biv
administ
antimicrobi
drug
longer
period
equivalentspectrum
antimicrobi
drug
select
deescal
antimicrobi
drug
perform
case
fever
crp
leukocyt
count
often
use
indic
treatment
respons
case
aspir
pneumonia
aspir
recur
treatment
despit
efficaci
antimicrobi
drug
necessari
evalu
whether
effect
antimicrobi
drug
obtain
recurr
occur
drug
recommend
empir
therapi
fig
case
risk
resist
bacteria
outpati
treatment
perform
group
accord
studi
chlamydophila
spp
pneumonia
account
patient
type
microorgan
caus
nhcap
clarifi
japan
respect
result
suggest
chlamydophila
spp
target
treatment
describ
cap
therefor
group
combin
therapi
blactam
macrolid
monotherapi
respiratori
quinolon
perform
bii
group
antip
aeruginosa
drug
combin
cpfx
pzfx
azm
inject
consid
legionella
chlamydophila
spp
pneumonia
howev
concern
combin
therapi
macrolid
cii
patient
without
sever
pneumonia
requir
intens
care
describ
evid
level
alway
high
perspect
medic
econom
side
effect
resist
bacteria
studi
examin
mortal
rate
respect
presenc
absenc
treatment
cover
atyp
pathogen
report
mortal
rate
significantli
lower
presenc
treatment
recent
metaanalysi
also
show
differ
respiratori
quinolon
establish
option
bii
base
mani
refer
describ
effect
similar
potent
combin
therapi
blactam
macrolid
howev
must
examin
consid
factor
sever
presenc
absenc
concomit
sepsi
furthermor
preval
penicillinresist
pneumococcu
intern
emphas
issu
macrolideresist
pneumococcu
markedli
observ
japan
also
background
factor
establish
respiratori
quinolon
option
previou
use
antimicrobi
drug
often
observ
patient
nhcap
consid
risk
factor
resist
pneumococcu
studi
report
penicillin
em
resist
hcap
patient
advanc
cap
patient
studi
indic
efficaci
oral
therapi
lvfx
similar
ctrx
inject
therapi
patient
cap
anoth
studi
report
among
patient
nonsever
hcap
oral
lvfx
use
descript
caus
microorgan
howev
aspir
pneumonia
suspect
grnx
mflx
select
effect
lvfx
anaerob
weak
furthermor
sever
studi
suggest
use
mflx
influenc
kidney
function
requir
dose
regul
elderli
patient
nhcap
treatment
complet
singl
high
dose
complianc
favor
azm
sustainedreleas
prepar
simultan
cover
bacteria
atyp
pathogen
stfx
show
favor
mic
anaerob
may
also
recommend
first
choic
cvaampc
oral
mg
time
day
sbtpc
oral
mg
time
day
tabl
risk
factor
involv
drugresist
pathogen
nhcap
histori
antibiot
therapi
day
preced
day
current
tube
feed
risk
mrsa
taken
account
whenev
past
histori
mrsa
isol
attempt
predict
isol
drugresist
pathogen
base
presenc
risk
factor
born
mind
sensit
neg
predict
valu
high
specif
posit
predict
valu
low
drugresist
pathogen
includ
pseudomona
aeruginosa
mrsa
acinetobact
esblproduc
enter
bacteria
stenotrophomona
maltophilia
tabl
possibl
pathogen
isol
nhcap
patient
nhcap
patient
risk
factor
involv
drugresist
pathogen
pneumococcu
mssa
gramneg
enter
bacteria
includ
klebsiella
e
coli
haemophilu
influenza
oral
streptococci
atyp
pathogen
particularli
chlamydophila
nhcap
patient
risk
factor
involv
drugresist
pathogen
follow
consid
addit
abovement
pathogen
pseudomona
aeruginosa
mrsa
acinetobact
esblproduc
enter
bacteria
one
follow
azm
sustainedreleas
prepar
oral
gsingl
dose
cam
oral
mgtwice
day
second
choic
mflx
oral
mgonc
day
grnx
oral
mgonc
day
stfx
oral
mgl
time
day
ctrx
intraven
drip
gonc
day
gtwice
day
ctx
intraven
drip
time
day
one
follow
azm
sustainedreleas
prepar
oral
gsingl
dose
cam
oral
mgtwice
day
antimicrobi
activ
drug
anaerob
insuffici
inappropri
tent
diagnosi
aspir
pneumonia
case
risk
resist
bacteria
hospit
treatment
perform
group
b
categori
recommend
monotherapi
perspect
caus
microorgan
resembl
cap
side
effectbas
innoc
properti
studi
report
initi
treatment
narrowspectrum
antimicrobi
drug
alway
lead
poor
prognosi
particular
accord
two
articl
necessari
consid
resist
bacteria
hcap
patient
caus
microorgan
unclear
treatment
accord
cap
treatment
suffici
bii
howev
advanc
age
central
nervou
diseas
aspir
reduct
adl
clinic
characterist
aspir
pneumonia
condit
nhcap
japan
overlap
aspir
pneumonia
therefor
group
b
patient
admit
first
time
recent
use
antimicrobi
drug
correspond
antimicrobi
therapi
blactamas
inhibitorcontain
penicillin
appropri
describ
cap
howev
aspir
pneumonia
suspect
ctrx
lvfx
avoid
biv
manag
enter
bacteria
candid
drug
group
b
papmbp
may
select
actual
necessari
consid
p
aeruginosa
patient
cap
nonicu
hap
studi
indic
ertapenem
effect
p
aeruginosa
use
demonstr
papmbp
howev
anoth
studi
report
widespread
use
ertapenem
induc
cross
resist
p
aeruginosa
carbapenem
use
papmbp
alon
avoid
biv
elderli
person
high
risk
aspir
repeatedli
admit
discharg
klebsiella
often
involv
tazpipc
use
accord
studi
bii
patient
gramneg
bacillu
detect
gram
stain
sputum
involv
enter
bacteria
suspect
papmbp
tazpipc
select
biv
sbtabpc
intraven
drip
time
day
ctrx
intraven
drip
gonc
day
gtwice
day
ctx
intraven
drip
time
day
lvfx
intraven
drip
mgonc
day
papmbp
intraven
drip
time
day
antimicrobi
activ
drug
anaerob
insuffici
inappropri
tent
diagnosi
aspir
pneumonia
case
risk
resist
bacteria
hospit
treatment
perform
group
c
target
microorgan
includ
p
aeruginosa
mrsa
acinetobact
spp
addit
frequent
microorgan
caus
respiratori
infect
antimicrobi
drug
tazpipc
antimicrobi
activ
p
aeruginosa
fourthgener
cephem
carbapenem
quinolon
cpfx
pzfx
recommend
taz
pipc
exhibit
effect
similar
ipmc
mepm
patient
nurs
healthcareassoci
pneumonia
bii
pzfx
also
antimicrobi
activ
pneumonia
use
high
dose
gday
pneumonia
relat
atyp
pathogen
chlamydophila
spp
suggest
quinolon
select
antimicrobi
activ
fourthgener
cephem
quinolon
anaerob
weak
drug
combin
mnz
cldm
sbtabpc
recent
resist
bacteroid
fragili
group
cldm
advanc
therefor
europ
unit
state
mnz
select
firstchoic
antimicrobi
drug
anaerob
howev
rate
b
fragili
group
involv
oral
anaerob
low
combin
therapi
cldm
may
select
therefor
combin
therapi
fourthgener
cephem
recommend
two
drug
risk
mrsa
previou
admiss
combin
vcm
teic
lzd
abscess
format
abk
also
effect
first
choic
tazpipc
intraven
drip
time
day
ipmc
intraven
drip
time
day
mepm
intraven
drip
time
day
drpm
intraven
drip
time
day
second
choic
cfpm
intraven
drip
time
day
cpr
intraven
drip
time
day
one
follow
cldm
intraven
drip
time
day
mnz
intraven
drip
time
day
cpfx
intraven
drip
mgtwice
day
pzfx
intraven
drip
mgtwice
day
one
follow
cldm
intraven
drip
time
day
sbtabpc
intraven
drip
time
day
addit
drug
mrsa
infect
suspect
antimicrobi
drug
ad
accord
section
mrsa
pneumonia
antimicrobi
activ
drug
anaerob
insuffici
combin
drug
antimicrobi
activ
anaerob
mnz
cldm
sbtabpc
tent
diagnosi
aspir
pneumonia
sever
case
requir
intens
care
group
cover
l
pneumophila
atyp
pathogen
rare
caus
microorgan
may
caus
sever
condit
groupc
antimicrobi
drug
combin
cpfx
pzfx
azm
inject
bi
concern
use
combin
therapi
blactam
macrolid
inject
sever
pneumonia
evid
accumul
studi
indic
sever
communityacquir
pneumonia
patient
sepsi
requir
icu
manag
combin
therapi
blactam
macrolid
led
favor
prognosi
compar
quinolon
suggest
antiinflammatori
action
involv
mechan
addit
anoth
studi
report
among
pneumonia
patient
acut
pulmonari
disord
ventil
withdraw
surviv
rate
macrolidetr
group
higher
nonmacrolidetr
group
sever
metaanalys
also
support
first
choic
tazpipc
intraven
drip
time
day
ipmc
intraven
drip
time
day
mepm
intraven
drip
time
day
drpm
intraven
drip
time
day
one
follow
cpfx
intraven
drip
mgtwice
day
pzfx
intraven
drip
mgtwice
day
azm
intraven
drip
mgonc
day
second
choic
cfpm
intraven
drip
time
day
cpr
intraven
drip
time
day
one
follow
cldm
intraven
drip
time
day
mnz
intraven
drip
time
day
one
follow
cpfx
intraven
drip
mgtwice
day
pzfx
intraven
drip
mgtwice
day
azm
intraven
drip
mgonc
day
addit
drug
mrsa
infect
suspect
antimicrobi
drug
ad
accord
section
mrsa
pneumonia
antimicrobi
activ
drug
anaerob
insuffici
combin
drug
antimicrobi
activ
anaerob
mnz
cldm
sbtabpc
tent
diagnosi
aspir
pneumonia
antimicrobi
drug
identifi
caus
microorgan
select
accord
section
hospitalacquir
pneumonia
p
execut
summari
oral
indigen
bacteria
includ
anaerob
caus
aspir
pneumonia
blactamas
inhibitorcontain
penicillin
appropri
bii
case
nosocomi
onset
necessari
cover
gramneg
bacillu
includ
p
aeruginosa
case
sever
ventilatorassoci
pneumonia
vap
select
broadspectrum
antimicrobi
drug
combin
therapi
hesit
ai
detect
rate
esblproduc
gramneg
bacillu
increas
antimicrobi
drug
care
select
import
prevent
subclin
aspir
oral
care
prevent
gastroesophag
reflux
head
lift
bii
prevent
aspir
pneumonia
also
import
improv
nutrit
statu
avoid
overus
sleep
pill
sed
bii
explan
characterist
classif
diseas
aspir
pneumonia
occur
background
factor
dysphagia
frequent
observ
presenc
reduct
adl
system
function
especi
cerebrovascular
disord
onset
associ
dietari
ingest
elderli
person
current
aspir
pneumonia
accur
defin
guidelin
manag
hospitalacquir
pneumonia
hap
adult
prepar
japanes
respiratori
societi
guidelin
present
condit
may
caus
dysphagia
propos
japanes
studi
group
aspir
pulmonari
diseas
tabl
modifi
guidelin
primarili
explain
antimicrobi
drug
select
patient
condit
definit
also
adopt
guidelin
manag
nurs
healthcareassoci
pneumonia
nhcap
elderli
person
admit
longterm
care
bed
nurs
home
risk
factor
includ
dysphagia
tubal
feed
accord
intern
data
pneumonia
develop
nurs
home
japan
frequent
underli
diseas
patient
nhcap
also
includ
central
nervou
diseas
dementia
close
associ
aspir
proport
patient
percutan
endoscop
gastrostomi
peg
high
howev
among
variou
type
communityacquir
pneumonia
diagnosi
aspir
pneumonia
made
base
onset
factorbas
classif
equal
nhcap
diagnos
primarili
base
place
onset
grade
nurs
accord
data
spain
aspir
pneumonia
account
patient
healthcareassoci
pneumonia
hcap
requir
admiss
percentag
markedli
higher
communityacquir
pneumonia
cap
requir
admiss
correspond
hand
multicent
cooper
studi
involv
inpati
pneumonia
japan
rapid
age
societi
advanc
report
patient
admit
cap
aspir
pneumonia
even
patient
cap
classifi
nhcap
involv
aspir
ignor
furthermor
studi
indic
involv
aspir
patient
age
year
cap
hap
futur
signific
distinguish
aspir
pneumonia
among
patient
nhcap
hap
chang
therapeut
strategi
examin
howev
nhcap
markedli
affect
adl
compar
cap
aspect
elderli
pneumonia
emphas
may
signific
posit
diagnos
aspir
pneumonia
establish
therapeut
strategi
differ
cap
concern
hap
reduct
immun
function
background
factor
hap
two
aspect
pneumonia
high
risk
resist
bacteria
central
nervou
diseaserel
aspir
involv
guidelin
manag
hospitalacquir
pneumonia
adult
prepar
japanes
respiratori
societi
mendelson
syndrom
vap
categor
group
classif
involv
diffus
deglutitionrel
bronchiol
find
pneumonia
propos
addit
flow
chart
diagnosi
present
fig
respect
condit
treatment
vap
refer
review
describ
chastr
et
al
manag
antimicrobi
drug
therapi
also
consid
bundl
tabl
base
prevent
perform
aii
type
frequenc
caus
microorgan
streptococcu
pneumonia
aureu
enterobacteriaca
report
studi
indic
k
pneumonia
frequent
involv
oral
indigen
bacteria
streptococcu
anginosu
group
anaerob
suggest
case
nosocomi
onset
gramneg
bacillu
includ
p
aeruginosa
must
also
consid
concern
e
coli
klebsiella
spp
proteu
spp
number
esblproduc
strain
may
increas
futur
rule
antimicrobi
drug
therapi
appropri
antimicrobi
drug
therapi
select
diagnosi
aspirationrel
pneumonia
insuffici
treatment
may
lead
fatal
condit
excess
treatment
may
increas
number
resist
bacteria
show
neg
effect
may
differ
option
empir
therapi
patient
vap
patient
show
sever
condit
diffus
deglutitionrel
bronchiol
start
treatment
acceler
hand
approach
prevent
pneumonia
aspir
avoid
aspir
import
oral
care
head
lift
improv
nutrit
statu
must
consid
overus
sleep
pill
sed
avoid
bii
best
option
standardtyp
aspir
pneumonia
antimicrobi
drug
exist
antimicrobi
activ
aerob
anaerob
sbtabpc
tazpipc
effect
anaerob
frequent
isol
respiratori
system
fusobacterium
spp
prevotella
spp
peptostreptococcu
spp
resist
rate
type
bacteria
two
regimen
low
regimen
also
recommend
first
choic
guidelin
establish
japanes
associ
anaerob
infect
research
howev
studi
report
previou
administr
antimicrobi
drug
adl
correl
frequenc
enterobacteriacaeor
p
aeruginosarel
pneumonia
retrospect
studi
involv
patient
aspir
pneumonia
show
frequenc
k
pneumoniaerel
pneumonia
base
studi
drug
select
chang
accord
previou
administr
antimicrobi
chemotherapeut
drug
patient
admit
gener
medic
ward
among
patient
hospitalacquir
pneumonia
broadspectrum
drug
select
sever
aspir
pneumonia
vap
bii
caus
microorgan
identifi
improv
condit
achiev
deescal
perform
drug
recommend
empir
therapi
risk
resist
bacteria
drug
potent
antimicrobi
activ
oral
anaerob
present
howev
articl
provid
highlevel
evid
regard
aspir
pneumonia
follow
drug
affect
intestin
flora
antimicrobi
drugassoci
diarrhea
may
occur
symptom
improv
delay
patient
must
promptli
admit
drip
tabl
condit
may
caus
dysphagia
bundl
prevent
ventilatorassoci
pneumonia
upper
bodi
lift
head
lift
discontinu
sed
sed
discontinu
day
evalu
whether
extub
possibl
addit
item
method
prevent
aspir
pneumonia
includ
oral
care
administr
drug
improv
deglutit
function
ace
inhibitor
cilostazol
improv
nutrit
statu
eatingswallow
rehabilit
antipneumococcu
vaccin
infus
therapi
perform
outpati
treatment
prolong
outpati
treatment
first
choic
cvaampc
oral
mg
time
day
sbtpc
oral
mg
time
day
second
choic
mflx
oral
mgonc
day
stfx
oral
time
day
grnx
oral
mgonc
day
hospit
treatment
diagnosi
aspir
pneumonia
made
sbtabpc
frequent
use
japan
kaneko
et
al
report
sensit
oral
anaerob
may
caus
aspir
pneumonia
peptostreptococcu
spp
prevotella
spp
fusobacterium
spp
sbtabpc
similar
tazpipc
effect
cldm
aspir
pneumonia
pulmonari
abscess
similar
sbtabpc
bi
sbtabpc
cldm
show
similar
effect
toler
aspir
pneumonia
respect
oral
anaerob
exclud
bacteroid
spp
still
suscept
cldm
random
clinic
trial
rct
indic
cldm
potent
cephem
first
choic
sbtabpc
intraven
drip
time
day
second
choic
cldm
intraven
drip
time
day
case
risk
resist
bacteria
sever
case
case
risk
resist
bacteria
sever
case
drug
select
accord
option
group
c
nhcap
tubal
feed
risk
factor
aspir
also
risk
factor
resist
bacteria
involv
enterobacteriaca
k
pneumonia
e
coli
suggest
empir
therapi
select
accord
case
risk
resist
bacteria
japan
proport
esblproduc
bacteria
sputum
cultur
patient
respiratori
infecti
diseas
less
number
esblproduc
bacteria
slightli
increas
must
consid
futur
studi
report
clinic
effect
tazpipc
nonesblproduc
k
pneumonia
potent
sbtabpc
caution
need
must
consid
case
aspir
pneumonia
classifi
hcap
enterobacteriaca
isol
frequenc
ignor
concern
aspir
pneumonia
occur
hospit
review
propos
antimicrobi
drug
select
regard
condit
hospitalacquir
pneumonia
empir
therapi
may
select
accord
guidelin
manag
hospitalacquir
pneumonia
publish
japanes
respiratori
societi
accord
studi
bipm
caus
kidney
dysfunct
elderli
patient
also
effect
civ
therefor
present
option
case
risk
resist
bacteria
mortal
rate
patient
vap
high
caus
microorgan
initi
cover
mortal
rate
may
increas
therefor
drug
select
regard
condit
sever
aspir
pneumonia
three
studi
report
group
tazpipc
select
drug
combin
aminoglycosid
vap
treatment
mortal
rate
lower
group
caz
select
particular
pneumonia
caus
p
aeruginosa
clinic
effect
tazpipc
potent
ipmc
bii
monotherapi
inform
cultur
protect
specimen
brush
psb
sampl
bronchoalveolar
lavag
bal
fluid
strongli
recommend
hand
observ
studi
indic
threedrug
therapi
two
antip
aeruginosa
drug
antimrsa
drug
deterior
prognosi
rct
conduct
futur
therefor
risk
resist
bacteria
least
broadspectrum
antimicrobi
drug
must
use
empir
therapi
howev
assum
caus
microorgan
refer
gram
stain
reaction
minimum
necessari
antimicrobi
drug
select
base
local
factor
antimicrobi
drug
suscept
pattern
type
bacteria
hospit
recent
entiti
ventilatorassoci
tracheobronch
vat
propos
disadvantag
aggress
treatment
discuss
multicent
cooper
studi
patient
vat
occur
icu
divid
two
group
without
antimicrobi
drug
therapi
result
compar
former
incid
vap
significantli
lower
mechan
ventilationfre
period
significantli
longer
addit
icu
mortal
rate
significantli
lower
hand
signific
differ
appear
resist
bacteria
two
group
first
choic
tazpipc
intraven
drip
time
day
ipmc
intraven
drip
time
day
mepm
intraven
drip
time
day
drpm
intraven
drip
time
day
bipm
intraven
drip
time
day
second
choic
cfpm
intraven
drip
time
day
cpr
intraven
drip
time
day
one
follow
cldm
intraven
drip
time
day
mnz
intraven
drip
time
day
lvfx
intraven
drip
mgonc
day
cpfx
intraven
drip
mgtwice
day
pzfx
intraven
drip
mgtwice
day
one
follow
cldm
intraven
drip
time
day
mnz
intraven
drip
time
day
sbtabpc
intraven
drip
time
day
mrsa
infect
suspect
antimicrobi
drug
administ
accord
section
mrsa
pneumonia
addit
drug
administr
period
antimicrobi
drug
recommend
treatment
period
hospitalacquir
pneumonia
day
howev
treatment
period
day
patient
pneumonia
relat
nonglucosefer
bacteria
p
aeruginosa
bii
concern
vap
studi
report
differ
clinic
effect
day
control
identifi
caus
microorgan
antimicrobi
drug
select
accord
section
hospitalacquir
pneumonia
mrsa
infect
suspect
antimicrobi
drug
select
accord
section
mrsa
pneumonia
bii
sever
refractori
case
efficaci
initi
treatment
suffici
combin
therapi
antifung
drug
also
consid
bii
effect
combin
therapi
azol
amphb
prepar
antagon
strain
combin
drug
avoid
aiii
target
treatment
diseas
antifung
drug
class
differ
drug
use
prevent
administr
use
biii
explan
characterist
diseas
symptom
diseas
develop
sever
immunocompromis
host
patient
receiv
chemotherapi
leukemia
hematopoiet
stem
cellorgan
transplant
symptom
fever
respond
broadspectrum
antimicrobi
drug
cough
dyspnea
sputum
bloodi
sputumhemoptysi
observ
laboratori
find
chest
xray
show
infiltr
shadow
typic
wedg
shadow
involv
pleura
base
thorac
ct
infiltr
nodular
shadow
halo
sign
case
observ
recoveri
phase
neutrophil
air
crescent
sign
note
increas
inflammatori
marker
crp
level
aspergillu
galactomannan
antigenposit
reaction
increas
bdglucan
level
use
diagnosi
howev
neither
sensit
specif
suffici
result
care
evalu
caus
microorgan
aspergillu
fumigatu
frequent
detect
recent
increas
number
patient
nonfumigatu
aspergillusrel
ipa
indic
specif
condit
lesion
sometim
form
nasal
sinu
brain
caution
need
earli
diagnosi
earli
treatment
import
success
treatment
diseas
drug
recommend
studi
report
group
vrcz
use
initi
treatment
ipa
result
treatment
favor
group
damph
use
furthermor
anoth
studi
indic
therapi
lamb
mgkgday
safer
mgkg
day
although
signific
differ
clinic
efficaci
cpfg
mcfg
itcz
also
antiaspergillu
activ
use
import
consid
differ
strategi
accord
appear
host
allergi
advers
event
interact
drug
use
treat
underli
diseas
b
chronic
progress
pulmonari
aspergillosi
cppa
execut
summari
japan
variou
diseas
type
aspergilloma
infiltr
enlarg
exist
caviti
includ
cppa
includ
variou
diseas
chronic
necrot
pulmonari
aspergillosi
cnpa
chronic
cavitari
pulmonari
aspergillosi
ccpa
chronic
fibros
pulmonari
aspergillosi
cfpa
refer
seri
syndrom
administr
antifung
drug
essenti
treatment
start
inject
symptom
find
stabil
inject
switch
oral
drug
initi
treatment
mcfg
cpfg
perform
ai
initi
treatment
itcz
vrcz
lamb
also
select
accord
host
underli
diseas
drug
use
treat
underli
diseas
mainten
therapi
itcz
vrcz
oral
prepar
recommend
aiii
explan
characterist
diseas
symptom
diseas
develop
host
organ
diseas
caviti
cystic
diseas
lung
bronchu
symptom
fever
sputum
bloodi
sputum
hemoptysi
dyspnea
observ
laboratori
find
chest
xray
ct
show
infiltr
shadow
enlarg
caviti
thicken
caviti
wallpleura
niveau
caviti
increas
crp
level
mani
patient
patient
posit
antiaspergillu
precipit
antibodi
neither
aspergillu
galactomannan
antigen
bdglucan
clue
diagnosi
caus
microorgan
fumigatu
frequent
detect
nonfumigatu
aspergillusrel
cppa
also
often
observ
drug
recommend
clinic
studi
japan
indic
mark
differ
efficaci
treatment
mcfgand
vrcztreat
group
wherea
mcfg
safer
anoth
studi
report
differ
treatment
result
mcfg
cpfg
phase
sever
symptom
fever
bloodi
sputum
treatment
start
use
inject
pulmonari
aspergilloma
classifi
two
type
simpl
complex
aspergilloma
base
grade
difficulti
resect
former
refer
aspergilloma
format
focu
thin
wall
cyst
without
accessori
lesion
peripheri
latter
refer
aspergilloma
format
caviti
deriv
strongli
destruct
exist
structur
lung
old
pulmonari
tuberculosi
bronchiectasi
mark
destruct
lesion
pleural
adhes
peripheri
caviti
drug
recommend
resect
select
first
choic
resect
imposs
medic
treatment
consid
prepar
lamb
perform
week
subsequ
treatment
continu
use
flcz
fflcz
japan
cryptococcu
gattii
infect
also
report
possibl
caus
fungu
must
isolatedidentifi
explan
characterist
diseas
symptom
diseas
often
asymptomat
detect
health
checkup
mani
case
laboratori
find
chest
xray
ct
show
solitari
multipl
nodular
infiltr
shadow
caviti
observ
lot
case
enhanc
inflammatori
marker
mani
case
glucuronoxylomannan
antigenposit
reaction
detect
caus
microorgan
diseas
caus
cryptococcu
neoforman
recent
infect
c
gattii
report
vancouv
canada
north
area
west
coast
unit
state
america
caution
need
c
gattii
primarili
distribut
tropic
subtrop
zone
infect
human
consid
rare
howev
sinc
patient
infect
c
gattii
report
pacif
coast
north
america
even
healthi
adult
infect
c
gattii
mortal
rate
high
drug
recommend
although
evid
regard
pulmonari
cryptococcosi
flcz
tablet
potent
activ
cryptococcu
frequent
select
patient
condit
stabl
absenc
underli
diseas
azol
drug
also
select
aii
lesion
local
resect
consid
combin
therapi
iron
chelat
agent
lamb
avoid
ai
explan
recent
increas
incid
infect
cunninghamella
also
indic
specif
condit
nasalbraintyp
dermal
dissemin
zygomycosi
observ
drug
recommend
current
amph
prepar
may
clinic
use
treat
zygomycosi
among
antifung
drug
avail
clinic
practic
japan
highdos
therapi
must
start
earli
possibl
damph
lamb
select
lamb
intraven
drip
mgkgonc
day
precaut
use
antifung
drug
confirm
packag
insert
vrcz
vision
disord
liver
dysfunct
neurolog
mental
advers
event
may
occur
combin
therapi
rfp
rbt
efavirenz
ritonavir
carbamazepin
longact
barbitur
pimozid
quinidin
sulfat
ergot
alkaloid
triazolam
contraind
drug
also
contraind
pregnant
women
rule
contraind
patient
ccr
ml
min
inject
blood
concentr
vrcz
may
vari
tdm
conduct
patient
mild
moder
liver
dysfunct
dose
regul
itcz
hepatopathi
congest
heart
failur
may
occur
combin
therapi
pimozid
quinidin
bepridil
simvastatin
triazolam
azelnidipin
ergotamin
nisoldipin
dihydroergotamin
vardenafil
eplerenon
blonanserin
sildenafil
tadalafil
aliskiren
dabigatran
itcz
oral
rivaroxaban
ergometrin
methylergometrin
contraind
drug
contraind
patient
sever
liver
diseas
pregnant
women
patient
ccr
mlmin
also
contraind
inject
flcz
hepatopathi
prolong
qt
may
occur
combin
therapi
triazolam
ergotamin
dihydroergotamin
quinidin
pimozid
contraind
drug
also
contraind
pregnant
women
fflcz
combin
therapi
triazolam
ergotamin
dihydroergotamin
quinidin
pimozid
contraind
drug
also
contraind
pregnant
women
lamb
advers
event
nephropathi
hypopotassiumemia
fever
may
occur
drug
contraind
leukocyt
transfus
cpfg
drug
safe
hepatopathi
may
occur
caution
need
combin
therapi
cyclosporin
tacrolimu
rfp
efavirenz
nevirapin
phenytoin
dexamethason
carbamazepin
mcfg
drug
safe
hepatopathi
may
occur
anorexia
myelopathi
may
occur
combin
therapi
tegafurgimeraciloteracil
potassiumcontain
drug
contraind
even
discontinu
tegafurgimeraciloteracil
potassiumcontain
drug
combin
therapi
avoid
within
day
drug
also
contraind
pregnant
women
drug
recommend
st
combin
drug
use
gold
standard
pcp
treatment
howev
larg
number
patient
treatment
discontinu
due
side
effect
recent
atovaquon
also
becam
avail
japan
secondchoic
drug
patient
mild
pcp
atovaquon
tablet
effect
st
combin
drug
moder
pcp
st
combin
drug
effect
signific
differ
due
small
number
subject
atovaquonetr
patient
incid
advers
event
administr
discontinu
lower
st
combin
drugtreat
patient
suggest
toler
high
administr
period
day
hivinfect
patient
day
nonhivinfect
patient
target
daili
dose
trimethoprim
mgkg
st
combin
drug
oral
time
day
st
combin
drug
intraven
drip
mg
time
day
infus
h
second
choic
pentamidin
intraven
drip
mgkgonc
day
infus
h
atovaquon
oral
suspens
ml
mg
atovaquon
twice
day
day
oral
administ
meal
adjuv
therapi
patient
pao
mmhg
aado
mmhg
room
air
one
drug
combin
corticosteroid
start
treatment
howev
dose
may
reduc
administr
may
discontinu
earli
phase
accord
symptom
respiratori
state
extrem
unfavor
puls
therapi
also
consid
prednisolon
day
oral
mgtwice
day
day
oral
mgtwice
day
day
oral
mgtwice
day
precaut
drug
confirm
packag
insert
st
combin
drug
baktar
tablet
fever
exanthema
digest
symptom
hepatopathi
nephropathi
blood
disord
may
occur
drug
may
interact
methotrex
sulfadoxin
pyrimethamin
diaphenylsulfon
sulfonyl
amidesulfonylurea
oral
drug
diabet
warfarin
phenytoin
cyclosporin
zidovudin
digoxin
tricycl
antidepress
lamivudin
drug
contraind
neonat
lowbirthweight
infant
pregnant
women
patient
defici
patient
renal
dysfunct
dose
reduct
must
consid
side
effect
hypoglycemia
hypotens
nephropathi
tast
disord
numb
tonguelip
ventricular
arrhythmia
exanthema
fever
may
occur
combin
therapi
zalcitabin
pfa
amiodaron
contraind
drug
contraind
patient
sever
ventilatori
disturb
atovaquon
nauseavomit
exanthema
diarrhea
may
occur
drug
care
administ
patient
sever
kidney
liver
dysfunct
drug
may
interact
rfp
rbt
tetracyclin
metoclopramid
zidovudin
acetaminophen
benzodiazepin
aciclovir
opioid
analges
drug
cephalosporin
antibiot
antidiarrh
drugslax
indinavir
h
cytomegaloviru
cmv
pneumonia
execut
summari
field
transplant
preemptiv
treatment
gcv
conduct
cmv
antigenemia
test
monitor
efficaci
preemptiv
treatment
vgcv
pfa
similar
gcv
diagnosi
cmv
pneumonia
made
treatment
gcv
promptli
start
aii
vgcv
pfa
recogn
altern
drug
gcv
bii
combin
therapi
antivir
drug
highdos
immunoglobulin
perform
aiii
explan
antimicrobi
drug
recommend
firstchoic
drug
cmv
pneumonia
treatment
gcv
frequent
use
pfa
use
treat
cmv
infect
aid
patient
experi
use
limit
patient
hematopoiet
stem
cell
transplant
initi
administr
first
choic
gcv
intraven
drip
mgkg
h
everi
h
week
anticmv
hightit
gamma
globulin
intraven
drip
gonc
day
first
day
second
choic
pfa
intraven
drip
mgkg
h
time
day
everi
h
week
anticmv
hightit
gamma
globulin
intraven
drip
gonc
day
first
day
pfa
intraven
drip
mgkg
h
twice
day
everi
h
week
anticmv
hightit
gamma
globulin
intraven
drip
gonc
day
first
day
mainten
administr
first
choic
gcv
intraven
drip
mgkg
h
day
day
week
gcv
intraven
drip
mgkg
h
day
day
week
regimen
complet
confirm
disappear
clinic
symptom
neg
reaction
two
consecut
cmv
antigenemia
test
second
choic
pfa
intraven
drip
mgkg
h
day
clinic
practic
japan
case
report
onceaday
administr
mg
kg
mainten
therapi
dose
exceed
mg
kg
avoid
administr
mgkg
twiceaday
administr
mgkg
commonli
select
regimen
complet
confirm
disappear
clinic
symptom
neg
reaction
two
consecut
cmv
antigenemia
test
precaut
drug
confirm
packag
insert
gcv
sever
leukopenia
neutropenia
anemia
thrombopenia
pancytopenia
aplast
anemia
bone
marrow
suppress
may
occur
anim
experi
show
drug
induc
transient
irrevers
spermatogen
dysfunct
reduc
fertil
human
drug
may
caus
spermatogen
dysfunct
anim
experi
demonstr
teratogen
mutagen
carcinogen
drug
presenc
renal
hypofunct
necessari
regul
dose
drug
contraind
patient
mark
bone
marrow
suppress
neutrophil
count
platelet
count
pregnant
women
may
interact
didanosin
zidovudin
ipmc
bone
marrowsuppress
kidney
functionaffect
drug
zalcitabin
st
combin
drug
cyclosporin
probenecid
mycophenol
mofetil
vgcv
prodrug
gcv
pfa
acut
renal
failur
shock
heart
failur
thrombophleb
convuls
may
occur
necessari
regul
dose
accord
kidney
function
combin
therapi
pentamidin
contraind
drug
contraind
patient
ccr
mlminkg
execut
summari
treatment
communityacquir
pneumonia
children
antimicrobi
drug
select
consid
age
sever
explan
patient
acut
respiratori
infecti
diseas
symptom
fever
nasal
discharg
pharyng
pain
cough
appear
new
infiltr
shadow
lung
imag
examin
chest
xray
ct
regard
pneumonia
patient
pneumonia
thorac
auscult
find
often
includ
accessori
murmur
attenu
respiratori
sound
patient
respiratori
infecti
diseas
consult
hospit
fever
cough
lesion
site
airway
estim
base
symptom
physic
find
fig
addit
thorac
find
necessari
check
presenc
absenc
dyspnea
sign
tachypnea
nasal
alar
breath
retract
breath
shoulder
breath
orthopnea
groan
cyanosi
consid
need
antimicrobialdrug
administr
option
antimicrobi
drug
pneumonia
classifi
three
type
bacteri
viral
atyp
pneumonia
base
caus
microorgan
type
frequenc
caus
microorgan
microorgan
caus
childhood
communityacquir
pneumonia
differ
among
age
accord
data
investig
caus
microorgan
base
lavag
sputum
cultur
japan
bacteri
viral
pneumonia
frequent
infantschildren
age
year
younger
age
year
incid
bacteri
viral
atyp
pneumonia
similar
age
year
incid
atyp
pneumonia
highest
fig
insuffici
howev
review
report
similar
find
tabl
children
easi
investig
caus
microorgan
institut
imposs
investig
caus
microorgan
treatment
must
perform
base
statist
frequenc
caus
microorgan
describ
howev
investig
possibl
etiolog
investig
possibl
rule
antimicrobi
drug
therapi
import
improv
efficaci
treatment
accur
predict
caus
microorgan
select
appropri
antimicrobi
drug
administr
method
whether
antimicrobi
drug
indic
must
comprehens
evalu
differenti
bacteri
viral
atyp
pneumonia
refer
age
sever
clinic
symptom
physic
find
laboratori
data
xray
find
rule
singl
antimicrobi
drug
select
type
microorgan
caus
pneumonia
identifi
antimicrobi
drug
select
deescal
consid
drug
suscept
pharmacokinet
clinic
symptom
physic
find
wet
cough
tachypnea
frequent
observ
children
bacteri
pneumonia
proport
labor
breathingfre
patient
high
children
mycoplasma
pneumonia
auscult
find
includ
intermitt
accessori
murmur
rale
regardless
type
pneumonia
children
mycoplasma
pneumonia
proport
auscult
find
mark
significantli
higher
group
children
chlamydia
pneumonia
fever
mild
cough
protract
thu
clinic
symptom
physic
find
show
characterist
relat
caus
microorgan
difficult
identifi
caus
microorgan
base
clinic
symptom
physic
find
alon
individu
patient
concern
laboratori
find
admiss
children
bacteri
viral
pneumonia
signific
differ
leukocyt
count
crp
level
erythrocyt
sediment
rate
two
group
p
howev
measur
overlap
onethird
patient
present
fig
briefli
imposs
accur
differenti
bacteri
viral
pneumonia
base
inflammatori
respons
reflect
leukocyt
count
crp
level
erythrocyt
sediment
rate
mycoplasma
pneumonia
character
increas
crp
level
erythrocyt
sediment
rate
mani
patient
show
normal
leukocyt
count
slight
decreas
paramet
furthermor
difficult
differenti
mycoplasma
viral
pneumonia
base
laboratori
data
chest
xray
chest
xray
find
show
characterist
relat
caus
microorgan
degre
difficult
identifi
caus
microorgan
individu
patient
import
evalu
sever
pneumonia
select
outpati
hospit
treatment
review
necess
antimicrobi
drug
rout
administr
oral
intraven
classif
sever
guidelin
manag
respiratori
infecti
diseas
children
japan
present
tabl
caus
microorgan
respect
age
children
communityacquir
pneumonia
sever
classif
childhood
pneumonia
reach
japan
intern
examin
futur
standard
outpatienthospit
treatment
rule
outpati
treatment
perform
mildstatu
patient
evalu
accord
sever
classif
hospit
treatment
mildstatu
patient
dehydr
addit
necessari
determin
admiss
outpati
treatment
lead
improv
symptom
consid
social
adapt
tabl
initi
antimicrobi
drug
therapi
examin
children
pneumonia
treatment
must
start
without
precis
inform
caus
microorgan
mani
case
basic
empir
therapi
perform
consid
sever
pneumonia
caus
microorgan
type
caus
microorgan
depend
age
sever
therefor
necess
antimicrobi
drug
examin
select
consid
age
sever
addit
bacteri
viral
atyp
pneumonia
differenti
comprehens
evalu
refer
clinic
symptom
physic
find
laboratori
find
xray
find
particular
acut
bronchitispneumonia
relat
intermedi
suscept
h
influenza
mic
mgml
manag
oral
ampc
abpc
intraven
inject
therapi
recent
number
abpcsuscept
strain
annual
decreas
proport
blnar
strain
mic
mg
tabl
agerel
distribut
microorgan
caus
pneumonia
children
immedi
birth
inflammatori
respons
admiss
children
pneumonia
ml
increas
rais
issu
respect
drug
select
involv
blnar
strain
suspect
highdos
ampc
new
oral
cephem
may
necessari
outpati
clinic
efficaci
outpati
antimicrobi
drug
blnar
strain
increas
futur
care
monitor
concern
hospit
treatment
clinic
effect
abpc
intraven
inject
day
result
suscept
test
clarifi
investig
approxim
patient
respond
therapi
exacerb
patient
nonrespond
patient
clinic
effect
insuffici
necessari
switch
antimicrobi
drug
pipc
ctx
ctrx
stabl
antimicrobi
activ
review
clinic
effect
pipc
childhood
bronchopulmonari
infect
respons
rate
result
satisfactori
concern
treatment
catarrhali
pneumonia
catarrhali
produc
blactamas
howev
examin
clinic
cours
ampc
effect
enzymat
activ
blactamas
produc
catarrhali
low
tabl
evalu
treatment
respons
administr
period
administr
period
antimicrobi
drug
shown
tabl
classif
sever
communityacquir
pneumonia
children
moder
sever
increas
number
resist
strain
pneumonia
h
influenza
deriv
respiratori
infecti
diseas
treat
communityacquir
pneumonia
antimicrobi
drug
administ
day
treatment
respons
evalu
day
children
diseas
progress
often
prompt
first
evalu
perform
day
younger
severestatu
children
day
improv
clinic
symptom
laboratori
data
achiev
antimicrobi
drug
continu
appropri
antimicrobi
drug
drug
suscept
clarifi
respect
administr
period
antimicrobi
drug
factor
type
caus
microorgan
patient
background
differ
among
individu
patient
therefor
difficult
establish
standard
criteria
pneumonia
c
pneumonia
slowli
prolifer
treatment
period
prolong
tabl
patient
infect
gener
bacteria
administr
antimicrobi
drug
discontinu
day
pyretolysi
howev
antimicrobi
drug
therapi
necessari
treat
aureu
pneumonia
manag
nonrespond
antimicrobi
drug
therapeut
effect
antimicrobi
drug
pneumonia
whether
diagnosi
pneumonia
correct
initi
investig
possibl
diseas
pneumonia
pneumonialik
shadow
must
review
tabl
rule
whether
expect
type
pathogen
microorgan
correct
examin
type
caus
microorgan
expect
possibl
resist
microorgan
consid
new
therapeut
strategi
devis
care
promptli
condit
exacerb
despit
treatment
switch
addit
examin
conduct
concept
regard
diagnosi
treatment
childhood
mycoplasma
pneumonia
often
difficult
make
diagnosi
mycoplasma
pneumonia
infect
base
serum
antibodi
titerposit
find
acut
stage
alon
mycoplasma
pneumonia
nucleic
acid
identif
test
lamp
method
conduct
make
definit
diagnosi
acut
stage
firstchoic
drug
mycoplasma
pneumonia
macrolid
use
effect
macrolid
evalu
base
pyretolysi
within
day
administr
treat
pneumonia
respond
macrolid
administr
tosufloxacin
tetracyclin
consid
necessari
howev
rule
tetracyclin
contraind
children
age
year
younger
antimicrobi
drug
administ
accord
administr
period
recommend
individu
drug
patient
sever
pneumonia
system
steroid
therapi
must
consid
howev
easi
steroid
administr
avoid
howev
mycoplasma
pneumonia
includ
bacteri
type
prepar
may
indic
drug
recommend
first
choic
case
risk
resist
bacteria
ampc
oral
time
day
sbtpc
oral
time
day
cdtrpi
oral
time
day
cfpnpi
oral
time
day
cftmpi
oral
time
day
case
infect
resist
bacteria
suspect
two
year
younger
ii
pretreat
antimicrobi
drug
within
week
iii
concomit
develop
otiti
media
iv
histori
pneumoniarep
otiti
media
ampc
oral
time
day
cvaampc
prepar
oral
mg
kgtwice
day
cdtrpi
oral
time
day
cfpnpi
oral
time
day
cftmpi
oral
time
day
case
onsetrecurrencerecrudesc
observ
despit
previou
treatment
tbpmpi
oral
mgkgtwice
day
tflx
oral
mgkgtwice
day
second
choic
azm
oral
mgkgonc
day
day
cam
oral
mgkgtwice
day
admiss
moder
gener
ward
first
choic
abpc
intraven
inject
drip
time
day
pipc
intraven
inject
drip
time
day
sbtabpc
intraven
inject
drip
mgkg
time
day
pneumonia
chlamydia
trachomati
c
pneumonia
infect
strongli
suspect
one
regimen
combin
macrolid
respect
administr
method
dose
refer
section
six
year
older
outpati
clinic
mild
second
choic
ctx
intraven
inject
drip
time
day
ctrx
intraven
inject
drip
mgkg
twice
day
mgkgday
admiss
sever
icu
papmbp
intraven
drip
time
day
mepm
intraven
drip
time
day
tazpipc
intraven
drip
time
day
legionellosi
rule
one
regimen
combin
macrolid
respect
administr
methoddos
refer
section
six
year
older
admiss
moder
gener
ward
six
year
older
outpati
clinic
mild
first
choic
azm
oral
mgkgonc
day
day
cam
oral
mgkgtwice
day
second
choic
ampc
oral
time
day
sbtpc
oral
time
day
cdtrpi
oral
time
day
cfpnpi
oral
time
day
cftmpi
oral
time
day
mino
oral
mgkgtwice
day
children
age
year
younger
use
drug
limit
drug
use
nonrespond
drug
first
choic
case
bacteri
pneumonia
suspect
abpc
intraven
inject
drip
time
day
pipc
intraven
inject
drip
time
day
sbtabpc
intraven
inject
drip
mg
time
day
ctx
intraven
inject
drip
time
day
ctrx
intraven
inject
drip
mg
kgonc
twice
day
mgkgday
case
atyp
pneumonia
suspect
azm
oral
mgkgonc
day
day
cam
oral
mgkgtwice
day
em
intraven
drip
time
day
mino
oral
intraven
drip
mgkgtwice
day
children
age
year
younger
use
drug
limit
drug
use
nonrespond
drug
case
imposs
differenti
bacteri
atyp
pneumonia
one
drug
select
choic
combin
em
oral
time
day
azm
oral
mgkgonc
day
day
cam
oral
mgkgtwice
day
em
intraven
drip
time
day
mino
oral
intraven
drip
mgkgtwice
day
children
age
year
younger
use
drug
limit
drug
use
nonrespond
drug
execut
summari
treatment
hospitalacquir
pneumonia
children
antimicrobi
drug
select
consid
sever
involv
resist
bacteria
empir
therapi
start
combin
two
drug
necessari
consid
variou
resist
microorgan
differ
communityacquir
pneumonia
biii
hospitalacquir
pneumonia
defin
pneumonia
newli
develop
h
admiss
ventilatorassoci
pneumonia
defin
pneumonia
develop
h
endotrach
intub
condit
may
becom
sever
due
underli
diseas
reduc
immun
capac
deterior
gener
condit
caus
drugresist
microorgan
mani
case
treatment
difficult
case
microorgan
acquir
commun
also
exist
hospit
environ
caus
hospitalacquir
pneumonia
children
report
adult
field
bacteria
caus
communityacquir
pneumonia
pneumonia
h
influenza
enter
bacteria
e
coli
k
pneumonia
aureu
nonglucosefer
bacteria
p
aeruginosa
acinetobact
spp
anaerob
caus
hospitalacquir
pneumonia
addit
gener
bacteria
also
fungu
virus
sometim
caus
hospitalacquir
pneumonia
patient
immunodefici
among
patient
nosocomi
infect
caus
microorgan
differ
drugresist
microorgan
involv
mani
case
children
easi
investig
caus
microorgan
drug
suscept
clarifi
contribut
success
treatment
therefor
lavag
aspir
sputum
cultur
conduct
investig
etiolog
possibl
rule
antimicrobi
drug
therapi
basic
empir
therapi
perform
consid
sever
pneumonia
underli
diseas
caus
microorgan
particular
involv
drugresist
microorgan
mrsa
extendedspectrum
blactamas
esbl
produc
bacteria
multidrugresist
p
aeruginosa
mdrp
must
alway
consid
treatment
empir
therapi
start
combin
two
drug
necessari
consid
variou
resist
microorgan
differ
communityacquir
pneumonia
state
resist
bacteria
differ
among
institut
antimicrobi
drug
option
custom
base
record
antimicrobi
drug
suscept
antibiogram
institut
consensu
regard
administr
period
antimicrobi
drug
reach
respect
administr
period
antimicrobi
drug
factor
type
caus
microorgan
patient
background
differ
among
individu
patient
nosocomi
infect
therefor
difficult
establish
standard
criteria
howev
complic
sever
immunodefici
pulmonari
suppur
lung
abscess
pleuriti
absent
antimicrobi
drug
administ
day
pyretolysi
day
consid
underli
diseas
immun
state
flexibl
manag
must
perform
children
diseas
progress
often
prompt
first
evalu
perform
day
younger
severestatu
children
day
improv
clinic
symptom
laboratori
data
achiev
antimicrobi
drug
continu
appropri
antimicrobi
drug
drug
suscept
clarifi
type
microorgan
caus
pneumonia
identifi
targetfocus
antimicrobi
drug
select
deescal
consid
drug
suscept
pharmacokinet
concern
multidrugresist
microorgan
import
promot
standard
prevent
strategi
control
nosocomi
infect
prevent
dropletcontact
infect
thoroughli
furthermor
oral
care
devis
postur
medic
contraind
head
lift
necessari
prevent
vap
articl
classif
sever
tabl
p
guidelin
manag
respiratori
infecti
diseas
children
japan
use
refer
section
pneumonia
children
communityacquir
pneumonia
drug
recommend
first
choic
caz
intraven
inject
drip
time
day
czop
intraven
inject
drip
time
day
cpr
intraven
inject
drip
time
day
necessari
one
regimen
combin
one
follow
drug
case
anaerob
infect
suspect
aspir
pneumonia
cldm
intraven
drip
children
immunodeficiencyblood
diseaserel
pneumonia
antimicrobi
drug
select
consid
underli
diseas
grade
immunodefici
involv
variou
caus
microorgan
initi
antimicrobi
drug
therapi
start
combin
two
drug
necessari
consid
variou
caus
microorgan
differ
communityacquir
pneumonia
biii
characterist
classif
diseas
immunodeficiencyblood
diseaserel
pneumonia
children
often
develop
hospit
characterist
hospitalacquir
pneumonia
mani
case
may
becom
sever
due
patient
unfavor
condit
underli
diseas
reduc
immun
capac
deterior
gener
condit
even
nonpathogen
microorgan
may
caus
pneumonia
mani
case
furthermor
drugresist
microorgan
often
caus
pneumonia
treatment
difficult
mani
case
achiev
multidisciplinari
comprehens
treatment
save
children
necessari
cooper
special
field
type
frequenc
caus
microorgan
microorgan
acquir
commun
presenc
variou
immunodefici
state
also
nonpathogen
microorgan
exist
hospit
environ
caus
immunodeficiencyblood
diseaserel
pneumonia
children
bacteria
caus
communityacquir
pneumonia
pneumonia
h
influenza
enter
bacteria
e
coli
k
pneumonia
aureu
nonglucosefer
bacteria
p
aeruginosa
acinetobact
spp
anaerob
caus
type
pneumonia
addit
gener
bacteria
also
fungu
virus
often
caus
type
pneumonia
furthermor
drugresist
microorgan
involv
mani
case
indic
hospitalacquir
pneumonia
type
immunodefici
caus
microorgan
monitor
precaut
diagnosi
humor
immunodefici
bacteri
opson
complement
activ
affect
patient
humor
immunodefici
prone
infect
gener
bacteria
among
immunodefici
patient
hyperigmemia
pneumocysti
pneumonia
consid
condit
relat
ligand
abnorm
cellular
immunodefici
addit
infect
gener
bacteria
infect
intracellular
parasit
bacteria
fungu
protozoa
may
becom
sever
protract
differenti
induct
b
killer
cell
lymphocyt
affect
erad
virusinfect
cell
inhibit
tabl
neutrophil
abnorm
neutrophil
abnorm
classifi
two
type
neutropenia
neutrophil
function
disord
patient
peripher
blood
absolut
neutrophil
count
anc
anc
estim
reach
within
h
regard
neutropenia
risk
higher
patient
anc
less
period
estim
exceed
day
mani
patient
neutropenia
show
purul
sputum
abnorm
find
chest
xray
even
presenc
pneumonia
therefor
fever
persist
thorac
ct
perform
earli
stage
microorgan
includ
gener
bacteria
gramposit
bacteria
gramneg
bacteria
fungu
virus
may
caus
pneumonia
particular
addit
neutropenia
earli
homolog
hematopoiet
stem
cell
transplant
infectionpron
featur
associ
humoralcellular
immunodefici
relat
administr
immunosuppress
persist
long
period
furthermor
concomit
develop
acutechron
graftversushost
diseas
gvhd
risk
factor
onset
pneumonia
addit
noninfecti
pulmonari
disord
relat
drugsradi
pretreat
may
occur
import
differenti
infecti
diseas
fig
repres
neutrophil
function
disord
chronic
granulomatosi
induc
activ
oxygen
product
disord
neutrophil
affect
bactericid
action
therefor
patient
disord
prone
infect
nonh
produc
catalaseposit
bacteria
aureu
k
pneumonia
e
coli
candida
spp
aspergillu
spp
complement
defici
patient
complement
defici
prone
infect
bacteria
capsul
pneumonia
h
influenza
capsul
strain
neisseria
meningitidi
children
easi
investig
caus
microorgan
drug
suscept
clarifi
contribut
success
treatment
therefor
variou
cultur
conduct
investig
etiolog
possibl
addit
test
variou
antigen
urinari
pneumoniaelegionella
antigen
bdglucan
aspergillu
antigen
cryptococcu
antigen
candida
antigen
cytomegaloviru
antigen
test
use
nucleic
acid
amplif
method
pcr
method
util
possibl
rule
antimicrobi
drug
therapi
initi
antimicrobi
drug
therapi
perform
consid
sever
pneumonia
underli
diseas
treatment
immunodeficiencyblood
diseaserel
pneumonia
children
antimicrobi
drug
therapi
also
basic
select
consid
caus
microorgan
describ
nosocomi
infect
involv
drugresist
microorgan
mrsa
extendedspectrum
blactamas
esbl
produc
bacteria
multidrugresist
p
aeruginosa
mdrp
must
alway
consid
treatment
initi
antimicrobi
drug
therapi
start
combin
two
drug
necessari
consid
variou
resist
microorgan
differ
communityacquir
pneumonia
state
resist
bacteria
differ
among
institut
antimicrobi
drug
option
custom
base
record
antimicrobi
drug
suscept
antibiogram
institut
consensu
regard
administr
period
antimicrobi
drug
reach
respect
administr
period
antimicrobi
drug
factor
type
caus
microorgan
patient
background
differ
among
individu
patient
nosocomi
infect
therefor
difficult
establish
standard
criteria
children
diseas
progress
often
prompt
first
evalu
perform
day
younger
severestatu
children
day
improv
clinic
symptom
laboratori
data
achiev
antimicrobi
drug
continu
appropri
antimicrobi
drug
drug
suscept
clarifi
type
microorgan
caus
pneumonia
identifi
targetfocus
antimicrobi
drug
select
deescal
consid
drug
suscept
pharmacokinet
monitor
cultur
airway
use
treat
immunodeficiencyblood
diseaserel
pneumonia
children
gener
prevent
method
present
tabl
addit
longterm
lowdos
macrolid
therapi
intermitt
administr
blactam
prevent
p
aeruginosa
fixat
effect
patient
chronic
bronchiti
chronic
granulomatosi
oral
administr
itcz
mgkgday
maximum
mgday
subcutan
inject
ifng
domest
standard
unitsm
time
week
use
prevent
infect
articl
classif
sever
tabl
p
guidelin
manag
respiratori
infecti
diseas
children
japan
use
refer
section
pneumonia
children
communityacquir
pneumonia
drug
recommend
pneumonia
relat
mild
immunodefici
initi
phase
admiss
sbtabpc
intraven
inject
drip
time
day
ctx
intraven
inject
drip
time
day
ctrx
intraven
inject
drip
mgkgtwice
day
pneumonia
relat
moderatesever
immunodefici
caz
intraven
inject
drip
time
day
czop
intraven
inject
drip
time
day
cpr
intraven
inject
drip
time
day
sever
case
papmbp
intraven
drip
time
day
mepm
intraven
drip
time
day
drpm
intraven
drip
time
day
tazpipc
intraven
drip
time
day
vcm
intraven
drip
time
day
abk
intraven
drip
mgkgonc
day
teic
intraven
drip
mgkgeveri
h
time
subsequ
mgkgonc
day
respons
amk
intraven
drip
mgkgtwice
day
tob
intraven
drip
time
day
necessari
antifung
drug
mcfg
st
combin
drug
addit
administ
aspergillu
infect
suspect
treatment
start
vrcz
lamb
instead
mcfg
patient
cellular
immunodefici
one
drug
combin
mcfg
st
combin
drug
earli
stage
neutrophil
abnorm
one
drug
combin
mcfg
earli
stage
legionellosi
rule
severest
case
one
regimen
combin
macrolid
respect
administr
methoddos
refer
section
communityacquir
pneumonia
six
year
older
admiss
moder
gener
ward
p
presenc
gcv
resist
intraven
drip
pfa
foscarnet
time
day
perform
execut
summari
treatment
neonat
pneumonia
antimicrobi
drug
select
differenti
congenit
acquir
pneumonia
initi
antimicrobi
drug
therapi
start
combin
two
drug
regard
condit
sever
system
infect
consid
variou
caus
microorgan
administr
method
dose
select
base
age
day
birth
weight
biii
characterist
classif
diseas
incid
neonat
pneumonia
high
accord
sakata
pneumonia
occur
approxim
neonat
admit
period
neonat
pneumonia
frequent
observ
portion
system
infect
repres
sepsi
singl
condit
classifi
two
type
congenit
acquir
pneumonia
case
neonat
pneumonia
caus
typic
symptom
fever
cough
comparison
infantil
childhood
pneumonia
neonat
protect
capac
infect
physiolog
immatur
often
lead
sever
condit
neonat
phase
artifici
respir
manag
perform
mani
case
ventilatorassoci
pneumonia
vap
frequent
observ
addit
mani
neonat
admit
neonat
intens
care
unit
nicu
long
period
therefor
incid
nosocomi
infect
high
type
frequenc
caus
microorgan
sever
type
congenit
pneumonia
includ
transplacent
infect
intrauterin
infect
relat
aspir
infect
amniot
fluid
prematur
ruptur
birth
canal
infect
vagin
discharg
deliveri
type
congenit
pneumonia
primarili
caus
variou
virus
cytomegaloviru
herp
simplex
viru
bacteria
streptococcu
agalactia
gb
e
coli
listeria
monocytogen
chlamydia
fungu
clinic
onset
perinat
pneumonia
frequent
observ
immedi
day
birth
postnat
pneumonia
usual
develop
week
birth
caus
virus
bacteria
viral
infect
may
occur
rs
viru
parainfluenza
viru
adenoviru
prevail
ward
howev
rare
lead
onset
pneumonia
frequent
caus
bacteria
includ
aureu
e
coli
p
aeruginosa
acinetobact
spp
enterobact
spp
legionella
spp
exist
environ
often
caus
nosocomi
infect
prematur
babi
gram
stain
tracheal
aspir
sampl
use
select
antimicrobi
drug
administ
initi
phase
children
easi
investig
caus
microorgan
drug
suscept
clarifi
contribut
success
treatment
therefor
blood
bronchial
lavag
fluid
cultur
conduct
investig
etiolog
possibl
rule
antimicrobi
drug
therapi
mani
neonat
system
infect
immunodefici
state
administr
method
dose
select
treatment
sepsi
use
therefor
sever
pneumonia
consid
bacteri
pneumonia
suspect
combin
therapi
abpc
ctx
commonli
select
initi
treatment
consid
l
monocytogen
infect
combin
therapi
abpc
recommend
caus
microorgan
identifi
antimicrobi
drug
select
refer
drug
suscept
case
vap
antimicrobi
drug
option
custom
base
record
drug
suscept
antibiogram
microorgan
caus
nosocomi
infect
institut
neonat
mark
agerel
differ
pharmacokinet
antimicrobi
drug
therefor
drug
must
care
administ
neonat
phase
concret
dose
establish
field
pediatr
use
administr
interv
prolong
accord
age
case
sever
asphyxia
acut
renal
failur
administr
interv
must
prolong
shorten
improv
kidney
function
consensu
regard
administr
period
antimicrobi
drug
reach
howev
standard
administr
period
day
respect
administr
methoddos
refer
section
xi
dose
neonat
neonat
diseas
progress
often
prompt
treatment
respons
evalu
day
day
improv
clinic
symptom
laboratori
data
achiev
antimicrobi
drug
continu
appropri
antimicrobi
drug
drug
suscept
clarifi
type
microorgan
caus
pneumonia
identifi
targetfocus
antimicrobi
drug
select
deescal
consid
drug
suscept
pharmacokinet
drug
recommend
execut
summari
pyothorax
refer
condit
pu
accumul
thorac
caviti
usual
pleural
effus
punctur
perform
diagnosi
pyothorax
made
base
result
variou
examin
macroscop
purul
pleural
effus
microorgan
detect
gram
stain
cultur
pleural
effus
pleural
effus
ph
biii
patient
acut
pyothorax
relat
communityacquir
pneumonia
treatment
perform
accord
communityacquir
pneumonia
consid
microorgan
caus
communityacquir
pneumonia
streptococcu
pneumonia
biii
patient
slowli
progress
pyothorax
mix
infect
oral
aerobesanaerob
frequent
observ
combin
therapi
pcg
abpc
cldm
mnz
show
antianaerob
activ
therapi
singl
antimicrobi
drug
antianaerob
activ
sbtabpc
select
biii
risk
multidrugresist
bacteria
monotherapi
carbapenem
combin
therapi
fourthgener
cephalosporin
cldm
mnz
combin
therapi
quinolon
cldm
mnz
consid
assum
esblproduc
enter
bacteria
resist
p
aeruginosa
anaerob
acinetobact
biii
result
culturesuscept
test
clarifi
antimicrobi
drug
chang
accord
aiii
penetr
aminoglycosid
thorac
caviti
poor
activ
reduc
ph
low
therefor
use
aminoglycosid
avoid
rule
biii
diagnosi
pyothorax
made
administr
appropri
antimicrobi
drug
start
drainag
must
perform
aii
possibl
attend
physician
consult
surgeon
earli
stage
aiii
patient
mark
pleural
thicken
multilocular
pleural
effus
thoracoscop
debrid
necessari
biii
addit
fibrinolyt
drug
streptokinas
administ
thorac
drain
surgic
intervent
thoracotomi
decort
perform
case
biii
explan
diagnosi
pyothorax
defin
condit
pu
accumul
thorac
caviti
definit
diagnost
object
reason
usual
pleural
effus
punctur
perform
diagnosi
pyothorax
made
base
result
variou
examin
macroscop
purul
pleural
effus
microorgan
detect
gram
stain
cultur
pleural
effus
pleural
effus
ph
caus
microorgan
pleural
effus
appear
patient
bacteri
pneumonia
lead
pyothorax
etiolog
factor
pyothorax
includ
surgeri
trauma
esophag
perfor
microorgan
caus
pyothorax
depend
etiolog
cours
presenc
bacteri
pneumonia
pyothorax
caus
microorgan
caus
bacteri
pneumonia
furthermor
acut
pyothorax
frequent
caus
pneumonia
aureu
howev
mani
patient
chronic
pyothorax
mix
infect
primarili
anaerob
involv
among
anaerob
fusobacterium
spp
especi
fusobacterium
nucleatum
prevotella
spp
peptostreptococcu
spp
bacteroid
spp
frequent
detect
accord
recent
studi
detect
rate
streptococcu
anginosu
group
high
mani
case
pyothorax
rel
slow
cours
associ
tuberculosi
must
consid
pulmonari
lesion
alway
concurr
exist
tubercul
pleuriti
treatment
random
compar
studi
regard
antimicrobi
drug
treatment
pyothorax
conduct
antimicrobi
drug
activ
microorgan
expect
obtain
cultur
select
administ
acuteonset
patient
risk
resist
bacteria
exampl
pyothorax
accompani
communityacquir
pneumonia
antimicrobi
drug
pcg
abpc
initi
select
consid
pneumonia
drug
simultan
cover
fusobacterium
peptostreptococcu
viridan
streptococcu
group
howev
prevotella
bacteroid
produc
blactamas
therefor
result
cultur
obtain
combin
therapi
antimicrobi
drug
activ
anaerob
cldm
mnz
therapi
singl
drug
sbtabpc
select
risk
multidrugresist
bacteria
monotherapi
carbapenem
select
first
choic
assum
esblproduc
enter
bacteria
resist
p
aeruginosa
acinetobact
fourthgener
cephalosporin
combin
cldm
quinolon
combin
cldm
sbtabpc
result
culturesuscept
test
clarifi
antimicrobi
drug
chang
accord
howev
cultur
anaerob
difficult
conduct
case
therefor
confirm
laboratori
one
type
bacteria
detect
cultur
test
despit
sever
type
bacteria
detect
gram
stain
pleural
effus
anaerob
must
also
consid
penetr
aminoglycosid
thorac
caviti
poor
activ
reduc
ph
low
therefor
pyothorax
treatment
use
aminoglycosid
gener
avoid
treatment
period
pyothorax
treatment
period
establish
howev
pneumonia
promptli
respond
treatment
thorac
drainag
success
achiev
patient
pneumoniarel
pyothorax
treatment
period
day
requir
patient
drainag
unsuccess
mark
pleural
thicken
encapsulatedseptumlik
pyothorax
treatment
period
week
often
requir
treatment
antimicrobi
drug
therapi
diagnosi
pyothorax
made
administr
appropri
antimicrobi
drug
promptli
start
drainag
necessari
pleural
fluid
purul
viscou
absenc
multilocular
pattern
chesttub
insert
routin
perform
posit
insert
confirm
use
thorac
ct
within
h
insert
wozniak
et
al
perform
multivari
analysi
involv
patient
pyothorax
indic
failur
first
drainag
strongli
correl
mortal
suggest
necess
earli
consult
surgeon
patient
mark
pleural
thicken
multilocular
pleural
effus
thoracoscop
debrid
necessari
addit
fibrinolyt
drug
streptokinas
administ
thorac
drain
surger
intervent
thoracotomi
decort
perform
case
drug
recommend
first
choic
sbtabpc
intraven
drip
time
day
second
choic
pcg
intraven
drip
time
day
abpc
intraven
drip
time
day
one
follow
cldm
intraven
drip
time
day
mnz
intraven
drip
time
day
case
risk
multidrugresist
bacteria
first
choic
tazpipc
intraven
drip
time
day
ipmc
intraven
drip
time
day
mepm
intraven
drip
time
day
drpm
intraven
drip
time
day
second
choic
cfpm
intraven
drip
time
day
czop
intraven
drip
time
day
cpr
intraven
drip
time
day
one
follow
cldm
intraven
drip
time
day
mnz
intraven
drip
time
day
second
choic
ii
lvfx
intraven
drip
mgonc
day
cpfx
intraven
drip
mgtwice
day
pzfx
intraven
drip
mgtwice
day
one
follow
cldm
intraven
drip
time
day
sbtabpc
intraven
drip
time
day
mnz
intraven
drip
time
day
respect
risk
multidrugresist
bacteria
refer
section
hospitalacquir
pneumonia
tabl
p
particular
mrsa
infect
must
consid
patient
nosocomi
onset
previou
administr
antimicrobi
drug
staphylococcu
infect
suspect
gram
stain
pleural
effus
antimrsa
drug
use
empir
therapi
mssa
identifi
caus
bacteria
deescal
perform
definit
therapi
antimicrobi
drug
caus
microorgan
identifi
select
accord
section
execut
summari
treatment
pyothorax
children
antimicrobi
drug
administ
investig
etiolog
use
thoracentesi
blood
cultur
possibl
addit
antimicrobi
drug
therapi
treatment
retent
fluid
pleural
effus
drainag
continu
drainag
must
also
consid
biii
characterist
classif
diseas
pleuriti
refer
inflamm
pleura
fluid
pleural
effus
retain
pleural
caviti
pleuriti
classifi
type
fibrin
dri
pleuriti
exud
wet
pleuriti
purul
pleuriti
pyothorax
base
condit
auscult
attenu
respiratori
sound
well
pleural
friction
rub
heard
percuss
dull
note
chronic
stage
local
pleural
thicken
variou
shape
observ
pu
obtain
thoracentesi
definit
diagnosi
pyothorax
made
protein
level
nonpurul
pleural
effus
high
tubercul
pleuriti
differenti
type
frequenc
caus
microorgan
previous
pyothorax
associ
aureu
mani
case
howev
recent
case
rare
accord
data
form
nation
survey
former
half
patient
pneumoniaeor
anaeroberel
pyothorax
mani
case
pleuriti
follow
pneumoniaeor
virusrel
pneumonia
decubitusview
imag
show
retent
pleural
effus
approxim
patient
mycoplasma
pneumonia
drug
suscept
caus
microorgan
clarifi
contribut
success
treatment
therefor
pleural
effus
obtain
thoracentesi
cultur
investig
etiolog
possibl
bacteri
infectionrel
pyothorax
suspect
intraven
inject
drip
sbtabpc
ctx
ctrx
select
communityonset
patient
without
underli
diseas
hand
combin
therapi
sbtabpc
intraven
inject
drip
cldm
intraven
drip
carbapenem
therapi
intraven
drip
start
underli
diseas
nosocomi
onset
consid
pneumonia
anaerob
h
influenza
aureu
base
gram
stain
reaction
pleural
effus
caus
microorgan
estim
antimicrobi
drug
must
review
necessari
tuberculosi
also
investig
administr
period
antimicrobi
drug
must
longer
pneumonia
type
caus
microorgan
patient
background
state
retentionfluid
drainag
differ
among
individu
patient
difficult
establish
standard
criteria
howev
target
administr
period
pyogen
ga
pneumonia
aureusrel
pyothorax
day
respect
treatment
respons
evalu
day
start
administr
improv
clinic
symptom
laboratori
data
achiev
antimicrobi
drug
continu
caus
microorgan
drug
suscept
clarifi
type
microorgan
caus
pneumonia
identifi
targetfocus
antimicrobi
drug
select
deescal
consid
drug
suscept
pharmacokinet
treatment
pyothorax
treatment
retent
fluid
pleural
effus
drainag
also
basic
procedur
addit
antimicrobi
drug
therapi
necessari
continu
drainag
perform
tabl
pleural
thicken
lead
underexpand
lung
decort
indic
widespread
applic
thoracoscop
surgeri
facilit
minim
invas
surgeri
drug
recommend
commun
onset
without
underli
diseas
sbtabpc
intraven
inject
drip
time
day
ctx
intraven
inject
drip
time
day
ctrx
intraven
inject
drip
mgkgtwice
day
communityacquir
infect
underli
diseas
nosocomi
onset
cldm
intraven
drip
time
day
sbtabpc
intraven
inject
drip
time
day
one
follow
drug
alon
administ
tazpipc
intraven
drip
time
day
papmbp
intraven
drip
time
day
mepm
intraven
drip
time
day
drpm
intraven
drip
time
day
definit
therapi
refer
section
communityacquir
pneumonia
definit
therapi
p
hospitalacquir
pneumonia
definit
therapi
p
tabl
indic
continu
drainag
case
pleural
effus
obtain
thoracentesi
purul
case
clinic
effect
achiev
antimicrobi
drug
therapi
alon
within
h
case
retent
fluid
affect
respiratori
function
execut
summari
initi
treatment
four
drug
inh
rfp
pza
eb
sm
administ
month
subsequ
rule
standard
treatment
two
drug
inh
rfp
administ
month
perform
mainten
treatment
ai
pza
use
initi
treatment
reason
inh
rfp
eb
sm
administ
month
initi
treatment
subsequ
standard
treatment
b
two
drug
inh
rfp
administ
month
perform
mainten
treatment
aii
patient
chest
xray
show
caviti
initi
consult
initi
treatment
septum
cultur
still
posit
complet
initi
treatment
mainten
treatment
prolong
month
addit
prolong
mainten
treatment
also
consid
patient
sever
tuberculosi
militari
tuberculosi
tuberculosi
central
nervou
system
immun
depress
relaps
tuberculosi
aii
treatment
latent
tuberculosi
infect
inh
administ
month
ai
tuberculosi
sourc
infect
resist
inh
oral
administr
inh
difficult
due
side
effect
rfp
use
secondchoic
drug
month
ai
explan
particular
method
name
standard
treatment
guidelin
manag
tuberculosi
japan
articl
name
also
use
secondari
assess
studi
examin
efficaci
rifapentin
inh
show
factor
unsuccess
treatmentrecurr
includ
caviti
chest
xray
start
treatment
posit
find
cultur
complet
initi
treatment
month
similarli
treatment
period
extend
month
patient
silicotuberculosi
unsuccess
treatmentrecurr
rate
high
recurr
rate
decreas
therefor
variou
guidelin
recommend
mainten
treatment
prolong
month
patient
caviti
show
posit
find
septum
cultur
complet
initi
treatment
comb
et
al
compar
result
treatment
group
treat
inh
rfp
pza
month
inh
rfp
month
treat
inh
rfp
month
report
efficaci
incid
side
effect
similar
base
studi
follow
regimen
recommend
standard
treatment
b
guidelin
manag
tuberculosi
japan
pza
use
reason
inh
rfp
eb
sm
administ
first
month
subsequ
two
drug
inh
rfp
administ
month
patient
infect
tuberculosi
develop
tuberculosi
regard
latent
tuberculosi
infect
ltbi
inh
administr
ltbi
decreas
incid
tuberculosi
previous
call
prevent
therapi
current
term
ltbi
treatment
decreas
incid
tuberculosi
correl
complianc
inh
mark
prevent
effect
may
achiev
complianc
higher
studi
involv
inh
administr
ltbi
patient
old
shadow
chest
xray
therapi
inhibit
onset
tuberculosi
patient
treat
month
respect
signific
differ
two
group
base
data
studi
recommend
period
standard
inh
administr
ltbi
month
howev
consensu
regard
effect
administr
period
month
reach
variou
aspect
includ
efficaci
complianc
expens
incid
side
effect
actual
administr
period
determin
base
complianc
incid
side
effect
ltbi
treatment
rfp
use
month
altern
drug
oral
administr
inh
imposs
reason
prevent
effect
rfp
onset
tuberculosi
ltbi
patient
may
similar
inh
furthermor
incid
liver
dysfunct
lower
relat
inh
howev
use
rfp
drug
interact
must
consid
drug
recommend
first
choic
inh
oral
mgkgonc
day
maximum
mg
day
rfp
oral
mgkgonc
day
maximum
mg
day
oral
administ
meal
rule
pza
oral
mgkgonc
day
maximum
mgday
eb
oral
mgkgonc
day
maximum
mgday
sm
intramuscular
inject
mgkgonc
day
maximum
mgday
time
week
drug
administ
month
subsequ
two
drug
inh
rfp
administ
month
second
choic
inh
oral
mgkgonc
day
maximum
mg
day
rfp
oral
mgkgonc
day
maximum
mg
day
oral
administ
meal
rule
eb
oral
mgkgonc
day
maximum
mgday
sm
intramuscular
inject
mgkgonc
day
maximum
mgday
time
week
drug
administ
month
subsequ
two
drug
inh
rfp
administ
month
japan
tanaka
et
al
conduct
combin
therapi
cam
mgkg
ebrfpkm
patient
indic
underw
initi
treatment
becam
neg
mac
concern
cam
mani
studi
report
correl
vitro
drug
suscept
treatment
respons
furthermor
studi
indic
azm
effect
cam
rbt
publish
drug
price
nhi
scheme
japan
also
approv
tuberculosi
nontubercul
mycobacterium
infect
includ
pulmonari
mac
infect
drug
interact
rbt
less
mark
rfp
rbt
use
firstchoic
drug
dissemin
mac
infect
hivinfect
patient
hand
rbt
induc
side
effect
uveiti
elderli
patient
pulmonari
mac
infect
frequent
develop
variou
side
effect
gastrointestin
disord
make
longterm
therapi
difficult
addit
studi
indic
rbt
effect
rfp
pulmonari
mac
infect
nonhivinfect
patient
therefor
rfp
select
firstchoic
drug
pulmonari
mac
infect
nonhivinfect
patient
kobashi
et
al
divid
patient
pulmonari
mac
infect
two
group
group
treat
cam
rfp
eb
sm
intramuscularli
inject
mgkg
time
week
month
group
treat
salin
conduct
random
doubleblind
compar
studi
smtreat
group
rate
cultur
sputum
becam
neg
higher
salinetr
group
vs
respect
highqual
studi
demonstr
use
combin
therapi
aminoglycosid
studi
howev
variou
guidelin
recommend
combin
therapi
sm
amk
km
perform
month
initi
phase
treatment
patient
caviti
sever
nodularbronchodilat
type
infect
base
experi
guidelin
unit
state
recommend
sm
amk
comment
studi
show
two
drug
sm
amk
effect
although
sm
frequent
use
japan
sm
km
recommend
base
result
studi
nontubercul
mycobacterium
infect
control
committe
japanes
societi
tuberculosi
recommend
follow
dose
administr
method
chemotherapi
pulmonari
mac
infect
opinion
regard
chemotherapi
pulmonari
nontubercul
mycobacterium
infect
revis
rfp
mgkg
mg
day
day
eb
mgkg
mg
day
day
cam
mgday
mgkg
day
two
divid
dose
mg
two
divid
dose
sm
km
mgkg
less
mg
intramuscularli
inject
time
week
cooper
statement
nontubercul
mycobacterium
infect
american
thorac
societyinfecti
diseas
societi
america
recommend
therapi
cam
mgday
azm
mgday
eb
mgkgday
rfp
mgkgday
mg
patient
caviti
sever
nodularbronchodilat
type
infect
addit
recommend
combin
therapi
sm
amk
mgkg
time
week
patient
age
year
mg
less
month
initi
phase
consid
treatment
period
establish
year
cultur
becom
neg
guidelin
base
evid
guidelin
manag
nontubercul
mycobacterium
infect
publish
british
thorac
societi
treatment
period
pulmonari
mac
infect
establish
year
futur
optim
treatment
period
investig
drug
recommend
cam
oral
time
day
mgtwice
day
rfp
oral
mgkgonc
day
maximum
mg
day
oral
administ
meal
rule
eb
oral
mgkgonc
day
maximum
mgday
severestatu
patient
cavitytyp
lesion
addit
regimen
intramuscular
inject
sm
km
ad
abscessu
sometim
suscept
lzd
tgc
tigecyclin
ketolid
unclear
whether
correl
drug
suscept
clinic
effect
combin
therapi
cam
sever
intraven
antimicrobi
drug
amk
cfx
ipmc
may
control
symptom
progress
pulmonari
infect
abscessu
howev
actual
hospit
requir
administ
intraven
antimicrobi
administr
period
limit
month
subsequ
treatment
oral
drug
perform
cam
reliabl
oral
drug
describ
hand
monotherapi
cam
avoid
perspect
resist
induct
although
studi
report
combin
therapi
lzd
quinolon
efficaci
establish
base
background
combin
surgic
resect
lesion
combin
chemotherapi
treatment
expect
achiev
complet
cure
pulmonari
infect
abscessu
lesion
local
drug
recommend
first
choic
base
result
drug
suscept
test
follow
antimicrobi
drug
combin
cam
oral
time
day
mgtwice
day
amk
intraven
drip
mgkgonc
day
ipmc
intraven
drip
time
day
time
day
surgeri
must
consid
treatment
period
least
month
cultur
becom
neg
execut
summari
treatment
childhood
tuberculosi
sever
drug
combin
administ
specif
period
aii
treatment
nontubercul
mycobacterium
infect
sever
drug
combin
administ
specif
period
howev
mycobacterium
often
resist
treatment
treatment
respons
surgeri
must
consid
ciii
explan
characterist
classif
diseas
japan
tuberculosi
still
import
infecti
diseas
encount
patient
chronic
infect
respond
gener
antimicrobi
drug
tuberculosi
consid
differenti
diagnosi
mycobacteria
cultur
classifi
two
type
tuberculosi
complex
nontubercul
mycobacteria
ntm
tuberculosi
major
type
tuberculosi
complex
strong
infect
human
human
childhood
tuberculosi
classifi
two
type
base
age
briefli
primari
tuberculosi
repres
hilar
lymph
node
tuberculosi
mening
develop
follow
primari
infect
characterist
infant
children
interv
infect
onset
short
morbid
rate
high
addit
diseas
may
lead
sever
condit
pulmonaryhilar
lymph
node
tuberculosi
infant
children
asymptomat
gener
condit
favor
even
presenc
fever
cough
mani
case
primari
tuberculosi
detect
base
dyspnea
unfavor
gener
condit
addit
fever
cough
mani
infantschildren
militari
tuberculosi
mening
hand
secondari
tuberculosi
caviti
lesion
nodular
shadow
lung
field
frequent
junior
high
school
student
older
symptom
cough
sputum
fever
thorac
pain
often
observ
children
sourc
infect
clarifi
detail
peripher
contact
screen
time
onset
usual
sourc
infect
clarifi
children
often
fathersmoth
grandfathersgrandmoth
childhood
tuberculosi
form
caviti
lung
field
tuberculosi
level
focu
lower
adult
mani
case
difficult
bacteriolog
histolog
make
definit
diagnosi
comparison
adult
tuberculosi
usual
possibl
make
definit
diagnosi
comprehens
evalu
epidemiologicalclin
inform
opportun
sourc
infect
contact
tuberculosi
patient
tuberculin
reactionor
quantiferon
tb
qft
base
verif
infect
imag
find
suggest
tuberculosi
chest
xray
find
verif
tuberculosi
sputum
gastric
juic
individu
resist
includ
grade
bcg
vaccinationacquir
immun
age
well
consid
treatment
respons
case
qft
use
test
method
quantit
measur
ifng
diagnos
tuberculosi
infect
without
influenc
bcg
howev
assess
infantschildren
examin
futur
definit
diagnosi
pulmonari
tuberculosi
made
base
chest
xray
find
alon
thorac
ct
facilit
detail
evalu
presenc
absenc
extent
tubercul
lesion
use
diagnosi
furthermor
imag
find
tuberculosi
chang
short
period
mani
case
nontubercul
mycobacterium
belong
mycobacterium
categori
report
tuberculosi
therefor
often
detect
mycobacteriumposit
smear
sputum
gaffki
posit
reaction
initi
patient
regard
infecti
tuberculosi
admit
tuberculosi
ward
symptom
imag
find
also
similar
nontubercul
mycobacteriumand
tuberculosisinfect
patient
unless
detect
bacteria
identifi
unless
either
gene
detect
use
nucleic
acid
amplif
method
difficult
differenti
two
type
bacteria
howev
import
recogn
tuberculosi
nontubercul
mycobacterium
infect
differ
diseas
import
point
nontubercul
mycobacterium
infect
transmit
human
human
differ
tuberculosi
infecti
diseas
human
therefor
necessari
isol
patient
rule
patient
requir
admiss
manag
gener
ward
public
hygieneassoci
problem
necessari
submit
report
health
center
type
frequenc
caus
microorgan
japan
number
patient
childhood
tuberculosi
markedli
decreas
number
newli
regist
patient
tuberculosi
decreas
children
age
year
howev
decreas
incid
smearposit
pulmonari
tuberculosi
import
sourc
infect
mark
great
urban
area
conclud
opportun
infect
children
favor
decreas
caution
need
number
patient
newli
develop
nontubercul
mycobacterium
infect
japan
estim
approxim
adult
field
account
patient
newli
develop
tuberculosi
howev
rel
low
children
approxim
patient
nontubercul
mycobacterium
infect
infect
avium
complex
avium
mycoboterium
intracellular
pulmonari
mac
infect
approxim
infect
cansasii
rule
antimicrobi
drug
therapi
characterist
antitubercular
chemotherapi
children
children
toler
rel
high
dose
per
bodi
weight
comparison
adult
respect
pharmacokinet
incid
side
effect
low
pediatr
field
treatment
inh
rfp
pza
childhood
pulmonari
tuberculosi
intern
select
standard
chemotherapi
three
drug
inh
rfp
pza
administ
everi
day
first
month
inh
rfp
everi
day
subsequ
month
drug
resist
suspect
drug
combin
sm
eb
initi
phase
result
resist
test
clarifi
patient
secondari
tuberculosi
combin
therapi
inh
rfp
pza
sm
eb
initi
perform
addit
rule
followup
must
continu
year
complet
treatment
hand
drug
resist
referr
anoth
hospit
discontinu
treatment
present
among
patient
drop
treatment
although
number
patient
small
necessari
support
resist
continu
treatment
particular
recent
number
patient
difficult
continu
treatment
increas
potent
complianc
support
must
consid
connect
direct
observ
therapi
dot
health
center
welfar
activ
side
effect
treatment
includ
liver
dysfunct
howev
maximum
ast
alt
level
approxim
administr
care
continu
without
discontinu
treatment
level
exceed
treatment
transient
discontinu
addit
administr
low
dose
conduct
confirm
normal
liver
function
dose
gradual
increas
liver
dysfunct
requir
chang
treatment
frequent
furthermor
increas
serum
uric
acid
level
continu
treatment
lead
normal
patient
arthralgia
prevent
tuberculosi
prevent
onset
tuberculosi
uninfect
person
bcg
vaccin
perform
concern
efficaci
consensu
regard
potent
prevent
effect
sever
dissemin
tuberculosi
tubercul
mening
militari
tuberculosi
reach
consid
import
tubercul
mening
prevent
bcg
vaccin
earli
phase
infanc
month
birth
earlier
accord
state
peripher
tuberculosi
preval
still
necessari
japan
treatment
latent
tuberculosi
prevent
onset
tuberculosi
person
histori
tuberculosi
treatment
latent
tuberculosi
convent
chemoprevent
conduct
largescal
control
studi
report
inh
therapi
decreas
incid
tuberculosi
approxim
drug
administr
risk
tuberculosi
onset
concret
flexibl
evalu
base
tuberculin
reaction
opportun
infect
age
state
bcg
vaccin
individu
patient
treatment
nontubercul
mycobacterium
infect
nontubercul
mycobacterium
infect
refractori
despit
combin
therapi
antitubercular
drug
particular
evid
regard
treatment
children
effect
monotherapi
weak
monotherapi
cam
may
lead
appear
camresist
bacteria
within
month
therefor
therapi
avoid
respons
kansasii
antitubercular
drug
rel
favor
cure
may
achiev
howev
pulmonari
mac
infect
often
resist
treatment
respons
surgeri
must
consid
recurr
complet
treatment
also
often
observ
drug
recommend
administr
period
longer
tuberculosi
patient
develop
vision
disord
consid
even
dose
respons
surgeri
must
consid
explan
acut
bronchiti
character
cough
persist
day
case
cough
persist
week
spontan
subsid
sputum
present
case
absent
other
sputum
may
purul
even
viral
infect
etiolog
involv
neither
chest
xray
ct
show
appear
new
abnorm
shadow
differ
pneumonia
virus
evid
infect
bacteria
directli
caus
acut
bronchiti
adult
without
underli
diseas
howev
studi
use
transtrach
aspir
method
japan
h
influenza
pneumonia
catarrhali
primarili
isol
patient
diagnos
bacteri
acut
bronchiti
absenc
chronic
lower
respiratori
infecti
diseas
underli
diseas
case
pertussi
cough
persist
particularli
long
period
paroxysm
cough
inspiratori
whoop
vomit
cough
may
occur
acut
bronchiti
caus
pneumonia
also
induc
sever
persist
cough
case
influenza
fever
headach
gener
malais
arthralgia
observ
furthermor
acut
viral
bronchiti
may
lead
acut
bacteri
exacerb
patient
chronic
respiratori
lesion
underli
diseas
fever
increas
amount
purul
sputum
observ
rule
underli
diseas
complic
absent
routin
administr
antimicrobi
drug
acut
bronchiti
recommend
control
symptom
cough
symptomat
therapi
perform
necessari
hand
antimicrobi
drug
treatment
macrolid
indic
patient
pertussi
treatment
catarrh
period
reduc
degre
durat
cough
antimicrobi
drug
necessari
prevent
infect
peripher
person
perform
antimicrobi
drug
treatment
acut
bronchiti
caus
pneumonia
c
pneumonia
macrolid
select
firstchoic
drug
howev
increas
macrolideresist
pneumonia
must
consid
case
influenza
antiinfluenza
therapi
conduct
within
h
onset
patient
underli
diseas
elderli
person
complic
bacteri
eg
pneumonia
infect
may
occur
follow
viral
infect
although
frequent
healthi
adult
acut
bronchiti
relat
bacteri
infect
includ
secondari
infect
strongli
suspect
base
coughsputum
fever
leukocytosi
find
suggest
presenc
caus
microorgan
gram
stain
sputum
despit
absenc
new
infiltr
shadow
chest
xray
antimicrobi
drug
treatment
consid
accord
treatment
communityacquir
bacteri
pneumonia
drug
recommend
complic
chronic
respiratori
diseas
administr
antimicrobi
drug
acut
bronchiti
recommend
rule
respect
select
antimicrobi
drug
acut
bronchiti
complic
chronic
respiratori
diseas
secondari
bacteri
infect
refer
section
miller
jone
classif
purul
sputum
saliva
complet
mucou
sputum
mucou
sputum
contain
small
volum
purul
sputum
sputum
purul
area
compris
smaller
sputum
purul
area
compris
sputum
purul
area
compris
greater
fever
short
breath
addit
bacteri
infectionrel
respiratori
symptom
increas
frequenc
cough
volum
purul
sputum
degre
purul
chronic
stabl
condit
underli
diseas
copd
bronchiectasi
old
pulmonari
tuberculosi
concern
laboratori
data
inflammatori
respons
involv
leukocyt
count
crp
level
enhanc
pao
often
reduc
blood
ga
analysi
imag
find
imag
find
necessari
differenti
chronic
respiratori
diseaserel
airway
infect
pneumonia
absenc
shadow
must
confirm
ct
also
perform
evalu
underli
diseas
pulmonari
emphysema
bronchiectasi
estim
caus
microorgan
gram
stain
possibl
collect
sputum
mani
patient
gram
stain
use
predict
caus
microorgan
differenti
respiratori
tract
infect
presenc
chronic
respiratori
diseas
persist
infect
accord
studi
tone
sputum
suggest
presenc
pathogen
microorgan
rather
degre
purul
macroscop
examin
also
necessari
sputum
involv
much
inform
import
sampl
sampl
collect
administr
antimicrobi
drug
collect
wakingup
earli
morn
ideal
evalu
degre
sputum
purul
miller
jone
classif
tabl
use
sampl
evalu
higher
caus
microorgan
may
predict
use
gram
stain
gram
stain
area
number
inflammatori
cell
larg
initi
search
low
magnif
detail
observ
conduct
high
magnif
administr
antimicrobi
drug
sputum
alway
submit
suscept
test
caus
microorgan
h
influenza
p
aeruginosa
catarrhali
pneumonia
frequent
detect
persist
infect
p
aeruginosa
often
observ
must
differenti
acut
exacerb
base
clinic
symptom
laboratori
data
addit
aureu
k
pneumonia
consid
involv
atyp
pathogen
c
pneumonia
mix
infect
virus
bacteria
must
also
consid
treatment
purpos
treatment
reduc
clinic
symptom
prevent
recurr
prolong
interv
subsequ
exacerb
inhibit
lung
tissu
damag
administr
appropri
antimicrobi
drug
reliev
clinic
symptom
maintain
respiratori
function
hand
inappropri
antimicrobi
drug
may
deterior
prognosi
induc
recurr
japan
resist
pneumonia
h
influenza
macrolid
blactam
advanc
sever
studi
report
new
quinolon
use
blactam
respiratori
quinolon
potent
antimicrobi
activ
type
caus
microorgan
resist
bacteria
concern
administr
period
studi
indic
efficaci
administr
day
similar
day
former
safer
latter
administr
period
shorten
drug
recommend
empir
therapi
intern
studi
support
use
blactam
howev
japan
resist
pneumonia
h
influenza
macrolid
blactam
advanc
p
aeruginosa
also
sometim
isol
therefor
use
blactam
macrolid
limit
patient
without
risk
factor
intern
compar
studi
report
efficaci
azm
sustainedreleas
prepar
similar
new
quinolon
howev
japan
longterm
administr
macrolid
perform
mani
patient
therefor
circumst
differ
betalactamaseproduc
strain
detect
approxim
h
influenza
strain
betalactamaseneg
ampicillinresist
blnar
strain
account
approxim
therefor
drug
suscept
unclear
new
quinolon
select
firstchoic
oral
antimicrobi
drug
drug
suscept
clarifi
switch
effect
narrowspectrum
drug
inject
penicillin
initi
select
follow
blactamas
inhibitorcontain
penicillin
carbapenem
new
quinolon
catarrhali
betalactamaseproduc
strain
account
catarrhali
strain
oral
antimicrobi
drug
macrolid
initi
select
follow
blactamas
inhibitorcontain
penicillin
secondthirdgener
cephem
new
quinolon
inject
blactamas
inhibitorcontain
penicillin
secondthirdgener
cephem
new
quinolon
carbapenem
select
p
aeruginosa
oral
drug
new
quinolon
select
inject
antip
aeruginosa
penicillin
cephem
monobactum
carbapenem
new
quinolon
select
drug
suscept
type
bacteria
markedli
differ
among
strain
drug
select
base
result
cultur
test
pneumonia
oral
drug
penicillin
initi
select
follow
new
quinolon
patient
risk
resist
bacteria
respiratori
quinolon
lvfx
grnx
select
inject
penicillin
ctrx
select
carbapenem
must
consid
severestatu
patient
explan
characteristicsclassif
diseas
dpb
chronic
inflammatori
diseas
respiratori
tract
frequent
observ
east
asian
includ
japanes
gender
differ
diseas
frequent
develop
person
age
year
often
detect
patient
histori
chronic
sinus
concomit
develop
chronic
sinus
diseas
classifi
categori
sinobronchi
syndrom
symptom
typic
symptom
dpb
persist
cough
purul
sputum
symptom
exert
short
breath
dyspnea
appear
accord
diseas
progress
patient
complic
chronic
sinus
purul
nasal
discharg
nasal
obstruct
observ
chest
xray
show
pulmonari
overexpans
diffus
scatter
nodular
shadow
thorac
hrct
reveal
diffus
centrilobular
nodular
shadow
furthermor
obstruct
respiratori
dysfunct
hypoxemia
increas
cold
agglutinin
valu
hemagglutin
method
observ
type
frequenc
caus
microorgan
patient
dpb
persist
respiratori
tract
infect
h
influenza
pneumonia
catarrhali
often
observ
howev
incid
persist
infect
p
aeruginosa
increas
progress
longterm
macrolid
therapi
previous
prognosi
dpb
unfavor
respiratori
failur
gradual
progress
repeat
acut
exacerb
relat
respiratori
tract
infect
lead
fatal
outcom
howev
prognosi
dpb
markedli
improv
sinc
longterm
macrolid
therapi
lowdos
administr
em
ring
macrolid
establish
earli
diagnosistreat
facilit
complet
cure
dpb
therefor
diagnosi
dpb
made
longterm
macrolid
therapi
start
promptli
drug
recommend
persist
infect
oral
administr
em
mgday
continu
month
evalu
clinic
effect
mani
case
improv
symptom
decreas
volum
sputum
achiev
within
month
start
administr
addit
improv
imag
find
respiratori
function
achiev
month
treatment
croup
syndrom
character
acut
laryng
stenosisassoci
respiratori
disturb
bark
cough
hoars
inspiratori
stridor
lesion
involv
larynx
also
tracheabronchu
diseas
sometim
call
laryngotracheobronch
etiolog
factor
classifi
two
type
infecti
noninfecti
allergi
foreign
bodyrel
factor
incid
infecti
croup
syndrom
high
infantschildren
age
year
type
frequenc
caus
microorgan
croup
syndrom
primarili
caus
virus
parainfluenza
viru
type
common
viru
addit
parainfluenza
viru
type
influenza
ab
viru
rs
viru
human
metapneumoviru
coronaviru
adenoviru
measl
viru
rel
frequent
isol
rule
antimicrobi
drug
therapi
case
croup
syndrom
caus
virus
antimicrobi
drug
necessari
therefor
studi
evalu
efficaci
antimicrobi
drug
patient
croup
syndrom
treatment
guidelin
regard
croup
syndrom
antimicrobi
drug
recommend
execut
summari
bronchiol
caus
virus
administr
antimicrobi
drug
necessari
ai
explan
bronchiol
acut
inflammatori
obstruct
diseas
involv
bronchiol
narrow
bronchiolar
lumen
relat
mucos
epitheli
injuri
inflammatorycel
infiltr
interstiti
edema
increas
mucu
secret
caus
air
trap
peripher
respiratori
tract
lead
obstruct
respiratori
disord
diseas
frequent
develop
children
age
year
younger
howev
infant
age
month
younger
account
type
frequenc
caus
microorgan
bronchiol
primarili
caus
virus
rs
viru
account
addit
parainfluenza
viru
human
metapneumoviru
adenoviru
influenza
viru
rel
frequent
isol
rule
antimicrobi
drug
therapi
case
bronchiol
caus
virus
antimicrobi
drug
necessari
basic
treatment
symptomat
therapi
doubleblind
compar
studi
involv
abpc
nontreat
group
azm
nontreat
group
abpc
intraven
injectionor
em
nontreat
group
respect
signific
differ
admiss
period
symptom
improv
howev
smallscal
doubleblind
compar
studi
report
interv
recoveri
camtreat
group
shorter
nontreat
group
accord
anoth
studi
incid
secondari
bacteri
infect
cours
rs
virusrel
bronchiol
differ
antimicrobi
drugtreat
nontreat
group
therefor
necessari
administ
antimicrobi
drug
children
bronchiol
routin
treatment
prevent
secondari
bacteri
infect
howev
followup
must
care
continu
cours
bronchiol
diagnosi
secondari
bacteri
infectionrel
pneumonia
otiti
media
made
antimicrobi
drug
therapi
start
execut
summari
bacteri
tracheiti
bacteri
diseas
rapid
progress
dyspnea
symptom
progress
antimicrobi
drug
use
even
definit
diagnosi
made
aiii
explan
fever
croup
syndromelik
coughstridor
initi
appear
respiratori
disord
rapidli
progress
specif
postur
saliv
dysphagia
characterist
acut
epiglott
definit
diagnosi
made
base
characterist
clinic
featur
purul
secret
respiratori
tract
case
later
view
larynx
xray
show
stenosi
larynx
diseas
frequent
develop
children
age
year
type
frequenc
caus
microorgan
aureusrel
tracheiti
account
approxim
follow
relat
catarrhali
h
influenza
streptococcu
pneumonia
streptococcu
pyogen
mix
infect
virus
bacteria
frequent
parainfluenza
viru
type
influenza
viru
often
detect
rule
antimicrobi
drug
therapi
antimicrobi
drug
intraven
administ
follow
reason
diseas
rapidli
progress
oral
administr
difficult
mani
case
empir
therapi
combin
therapi
vcm
may
effect
infect
aureu
includ
mrsa
thirdgener
cephem
ctrx
ctx
potent
antimicrobi
activ
catarrhali
h
influenza
pneumonia
pyogen
perform
administr
period
day
drug
recommend
refer
section
pneumonia
children
drug
recommend
definit
therapi
p
execut
summari
acut
bronchiti
primarili
caus
virus
necess
antimicrobi
drug
administr
low
ai
acut
bronchiti
caus
pneumonia
c
pneumonia
b
pertussi
antimicrobi
drug
administ
necessari
aiii
secondari
infect
pneumonia
h
influenza
may
occur
although
incid
unclear
therefor
improv
administr
antimicrobi
drug
consid
aiii
explan
characterist
classif
diseas
bronchiti
caus
symptom
cough
fever
gener
malais
variou
caus
microorgan
induc
inflamm
epitheli
tracheobronchi
tissu
lead
onset
bronchiti
clinic
special
find
auscult
rough
respiratori
sound
intermitt
accessori
murmur
heard
chest
xray
also
show
mark
infiltr
shadow
usual
patient
interv
onset
less
week
regard
acut
bronchiti
howev
bronchiti
diagnos
japan
slightli
differ
europ
unit
state
latter
primarili
caus
persist
cough
japan
patient
find
chest
xray
despit
clinic
sign
pneumonia
chest
xray
perform
often
diagnos
bronchiti
diseas
entiti
must
arrang
type
frequenc
caus
microorgan
virus
rhinoviru
influenza
viru
rs
viru
adenoviru
parainfluenza
viru
human
metapneumoviru
human
bocaviru
account
caus
microorgan
pneumonia
c
pneumonia
b
pertussi
also
caus
bronchiti
although
case
rel
rare
rule
antimicrobi
drug
therapi
acut
bronchiti
primarili
caus
virus
administr
antimicrobi
drug
necessari
metaanalysi
compar
adult
antimicrobi
drug
administ
bronchiti
treatment
nontreat
adult
indic
differ
efficaci
report
clinic
studi
involv
children
publish
scale
small
object
data
insuffici
studi
report
antimicrobi
drug
effect
howev
secondari
bacteri
infect
follow
viral
infect
caus
fever
purul
sputum
leukocytosi
increas
crp
level
antimicrobi
drug
administ
consid
pneumonia
h
influenza
indic
antimicrobi
drug
administr
includ
pneumonia
c
pneumonia
b
pertussisrel
bronchiti
protract
cough
pneumoniaeor
c
pneumoniaerel
bronchiti
tend
show
spontan
cure
administr
antimicrobi
drug
alway
necessari
necess
administr
evalu
consid
sever
symptom
cours
respect
indic
administr
method
refer
section
pneumonia
children
firstchoic
drug
pneumonia
c
pneumonia
b
pertussisrel
bronchiti
macrolid
patient
b
pertussisrel
bronchiti
antimicrobi
drug
reliev
symptom
catarrh
period
b
pertussisrel
bronchiti
suspect
base
clinic
symptom
previou
vaccin
lymphocytepredomin
leukocytosi
antipt
antibodi
titer
lamp
find
antimicrobi
drug
use
howev
ring
macrolid
ineffect
b
pertussisrel
bronchiti
symptom
similar
pneumonia
chest
xray
show
abnorm
imposs
strictli
differenti
bronchiti
pneumonia
due
difficulti
chest
xray
treatment
perform
accord
pneumonia
drug
recommend
secondari
bacteri
infect
viral
infect
case
fever
purul
sputum
leukocytosi
increas
crp
level
observ
first
choic
ampc
oral
time
day
sbtpc
oral
time
day
cdtrpi
oral
time
day
cfpnpi
oral
time
day
cftmpi
oral
time
day
second
choic
azm
oral
mgkgonc
day
day
cam
oral
mgkgtwice
day
definit
therapi
b
pertussi
em
oral
time
day
cam
oral
mgkgtwice
day
azm
oral
mgkgonc
day
day
pneumonia
macrolidesensit
strain
em
oral
time
day
azm
oral
mgkgonc
day
day
cam
oral
mgkgtwice
day
macrolideresist
strain
mino
oral
intraven
drip
mgkgtwice
day
children
age
year
younger
use
drug
limit
drug
use
nonrespond
tflx
oral
mgkgtwice
day
administr
limit
children
age
year
younger
mino
use
chlamydia
c
pneumonia
c
psittaci
c
trachomati
em
oral
time
day
azm
oral
mgkgonc
day
day
cam
oral
mgkgtwice
day
influenza
execut
summari
protein
inhibitor
neuraminidas
inhibitor
nai
commerci
avail
antiinfluenza
drug
juli
influenza
virus
season
influenza
report
resist
amantadin
protein
inhibitor
use
japan
use
drug
antiinfluenza
drug
avoid
influenza
outbreak
period
antiinfluenza
therapi
promptli
start
base
clinic
diagnosi
even
patient
influenzalik
symptom
show
neg
result
rapid
diagnosi
kit
influenza
complet
rule
ai
nai
significantli
improv
influenza
surviv
nai
administr
within
day
onset
significantli
reduc
rate
condit
becom
sever
ai
current
follow
nai
select
japan
outbreak
period
appropri
drug
select
base
patient
background
latest
inform
preval
influenza
strain
oseltamivir
oral
efficaci
b
resist
mutant
zanamivir
inhal
efficaci
type
ab
laninamivir
inhal
efficaci
type
ab
peramivir
intraven
drip
efficaci
type
ab
drug
recommend
metaanalysi
antiinfluenza
drug
oseltamivir
zanamivir
juli
howev
shown
earli
introduct
antiinfluenza
therapi
influenza
significantli
inhibit
mortal
admiss
rate
also
incid
influenzaassoci
pneumonia
otiti
media
ischem
heart
diseas
comparison
symptomat
therapi
nai
laninamivir
peramivir
also
confirm
effect
oseltamivir
time
develop
ai
outpati
treatment
oseltamivir
oral
mgtwice
day
day
rule
administr
childrenadolesc
age
year
avoid
zanamivir
inhal
mgtwice
day
day
laninamivir
inhal
mgsingl
dose
peramivir
intraven
drip
mgsingl
dose
hospit
treatment
patient
sever
lifethreaten
influenza
patient
sever
lifethreaten
influenza
requir
admiss
respiratori
failur
encephalopathi
present
either
case
complic
must
treat
rule
nai
introduc
within
h
onset
influenza
obtain
effect
oseltamivir
oral
mgtwice
day
day
rule
administr
childrenadolesc
age
year
avoid
peramivir
intraven
drip
mgsingl
dose
drug
repeatedli
administ
everi
day
accord
symptom
nonlifethreaten
influenza
patient
pneumonia
oseltamivir
oral
mgtwice
day
day
rule
administr
childrenadolesc
age
year
avoid
peramivir
intraven
drip
mg
mg
patient
condit
may
becom
sever
singl
dose
drug
repeatedli
administ
everi
day
accord
symptom
nonlifethreaten
influenza
patient
without
pneumonia
oseltamivir
oral
mgtwice
day
day
rule
administr
childrenadolesc
age
year
avoid
zanamivir
inhal
mgtwice
day
day
laninamivir
inhal
mgsingl
dose
peramivir
intraven
drip
mgsingl
dose
drug
repeatedli
administ
everi
day
accord
symptom
patient
basic
treatment
earli
administr
antiinfluenza
drug
accord
articl
signific
differ
viral
level
mortal
rate
day
start
administr
doubleand
standarddos
oseltamivir
therapi
howev
treatment
start
within
h
onset
patient
articl
execut
summari
influenza
caus
influenza
viru
antimicrobi
drug
necessari
recommend
neuraminidas
inhibitor
administ
within
h
onset
ai
pneumonia
otiti
media
occur
secondari
bacteri
infect
administr
antimicrobi
drug
must
consid
biii
explan
characterist
classif
diseas
influenza
often
appear
sudden
fever
shiver
headachegener
malaisemuscular
paindri
cough
follow
mark
respiratori
digest
symptom
underli
diseasefre
children
recoveri
achiev
day
howev
outbreak
period
even
underli
diseasefre
children
often
admit
seriou
symptom
encephalopathi
myocard
pneumonia
requir
artifici
respir
although
outbreak
period
decemb
march
everi
year
outbreak
observ
summer
area
type
frequenc
caus
microorgan
sinc
influenza
prevail
outbreak
type
influenza
b
repeat
incid
differ
among
year
rule
antimicrobi
drug
therapi
antimicrobi
drug
indic
influenza
recommend
neuraminidas
inhibitor
administ
within
h
onset
dose
neuraminidas
inhibitor
approv
japan
present
tabl
cours
influenza
bacteri
infect
pneumonia
otiti
media
may
occur
previous
incid
secondari
bacteri
infect
children
exceed
less
sinc
neuraminidas
inhibitor
develop
howev
bacteri
infect
observ
severestatu
patient
requir
intens
care
streptococcu
pneumonia
aureu
h
influenza
frequent
detect
caus
microorgan
studi
demonstr
prophylact
administr
antimicrobi
drug
onset
influenza
prevent
secondari
bacteri
infect
among
children
influenza
antimicrobi
drug
therapi
consid
sign
pneumonia
otiti
media
subsid
despit
administr
neuraminidas
inhibitor
parasit
diseas
respiratori
system
execut
summari
parasit
diseas
wide
distribut
throughout
world
addit
domest
infect
japanes
travel
may
infect
oversea
endem
area
furthermor
parasit
diseas
alway
consid
foreign
patient
endem
area
biv
peripher
blood
eosinophilia
observ
addit
respiratori
symptom
abnorm
find
chest
imag
examin
perform
differenti
parasit
diseas
biv
parasit
diseas
respiratori
system
caus
paragonimu
spp
ascari
lumbricoid
ancylostoma
duodenal
necat
americanu
strongyloid
stercorali
toxocara
cani
toxocara
cati
wuchereria
bancrofti
brugia
malayi
dirofilaria
immiti
two
major
diagnost
test
parasit
diseas
detect
parasit
egg
larva
sputum
stool
detect
parasitespecif
antibodi
use
serum
pleural
effus
sampl
immunodiagnosi
antiparasit
antibodi
screen
test
speci
parasit
commerci
avail
paragonimu
spp
strongyloid
sp
cani
immiti
ascari
suum
anisaki
simplex
gnathostoma
spp
fasciola
hepatica
clonorchi
sinensi
spirometra
erinaceieuropaei
cysticercu
cellulosa
diagnosistreat
consult
regard
parasit
diseas
japanes
societi
parasitolog
avail
refer
homepag
http
jsptmnagasakiuacjp
explan
paragonimu
spp
sever
paragonimu
speci
known
caus
human
infect
paragonimu
westermani
p
miyazakii
distribut
japan
infect
occur
consumpt
freshwat
crab
intermedi
host
eriocheir
japonica
e
sinensi
geothelphusa
dehaani
wild
boar
paraten
host
su
scrofa
contamin
metacercaria
infect
larva
raw
insuffici
cook
food
typic
symptom
cough
sputum
thorac
pain
exert
dyspnea
patient
symptom
presenc
peripher
blood
eosinophilia
suggest
diseas
mani
case
diagnosi
made
base
peripher
blood
eosinophilia
histori
take
food
tabl
standard
dose
neuraminidas
inhibitor
children
oseltamivir
oral
mgkg
twice
day
day
use
drug
avoid
childrenadolesc
age
year
zanamivir
b
inhal
mg
twice
day
day
laninamivir
inhal
year
older
mg
year
younger
mg
singl
dose
peramivir
intraven
drip
mgkg
day
prevent
administr
drug
mgkg
day
day
approv
cover
health
insur
b
prevent
administr
drug
mg
day
day
approv
cover
health
insur
immunodiagnosi
paragonimiasi
patient
asymptomat
presenc
lung
lesion
detect
health
checkup
extrapulmonari
paragonimiasi
cutan
cerebr
paragonimiasi
classic
known
form
ectop
infect
paragonimu
spp
case
cutan
paragonimiasi
slowli
move
nodular
lesion
subcutan
tissu
characterist
symptom
worm
may
migrat
mediastin
soft
tissu
brain
caus
eosinophil
mening
cerebr
paragonimiasi
case
sinc
paragonimu
spp
wide
distribut
around
world
japanes
travel
endem
area
china
korea
thailand
philippin
possibl
infect
paragonimu
spp
well
foreign
patient
endem
area
diseas
alway
consid
patient
respiratori
symptom
andor
lung
lesion
eosinophilia
chest
xray
find
vari
pulmonari
parenchym
lesion
nodular
format
infiltr
shadow
also
pleural
lesion
retent
pleural
effus
pneumothorax
sometim
observ
mani
patient
show
peripher
blood
eosinophilia
andor
elev
serum
total
ige
immunodiagnosi
detect
parasitespecif
antibodi
proven
use
reliabl
tool
patient
serum
also
pleural
effus
could
examin
immunolog
test
commerci
avail
antiparasit
antibodi
screen
test
includ
paragomimu
spp
japan
eggdetect
rate
among
paragonimiasi
patient
nowaday
low
exampl
sputum
balf
bronchoscop
aspir
definit
diagnosi
made
oral
treatment
start
type
treatment
select
outpati
hospit
treatment
depend
patient
gener
condit
howev
usual
outpati
treatment
possibl
patient
pleural
effus
pleural
fluid
must
extens
drain
start
chemotherapi
biii
patient
chronic
encapsul
pleural
effus
surgeri
requir
ciii
drug
recommend
first
choic
dose
adult
children
praziquantel
oral
time
day
day
aiii
lumbricoid
duodenal
n
americanu
larva
parasit
pass
lung
human
bodi
caus
asthmaor
pneumonialik
symptom
transient
fever
cough
dyspnea
chest
xray
transient
nodularinfiltr
shadow
observ
mani
patient
show
peripher
blood
eosinophilia
andor
elev
serum
total
ige
previous
condit
call
loffler
syndrom
current
classifi
simpl
pulmonari
eosinophilia
categori
pie
syndrom
symptom
appear
week
oral
ingest
lumbricoid
embryon
egg
latenc
period
percutan
infect
n
americanu
larva
percutaneousor
infect
duodenal
larva
approxim
day
larva
appear
small
intestin
penetr
intestin
wall
enter
portal
vein
migrat
liver
heartlung
larva
penetr
human
skin
transfer
lung
blood
flow
larva
migrat
bronchi
trachea
epiglotti
esophagusstomach
reach
small
intestin
intestin
larva
develop
matur
adult
simpl
pulmonari
eosinophilia
relat
parasit
spontan
resolv
week
mani
case
definit
diagnosi
made
base
parasit
egg
detect
stool
examin
although
larva
sometim
detect
sputum
drug
recommend
first
choic
dose
adult
children
pyrantel
pamoat
oral
mgkgsingledos
administr
dri
syrup
children
avail
drug
effect
adult
worm
intestin
tract
larva
migrat
human
bodi
therefor
stool
examin
perform
week
oral
administr
parasit
egg
detect
addit
administr
conduct
second
choic
dose
adult
children
albendazol
oral
mgsingledos
administr
mebendazol
oral
mgtwice
day
day
mgsingledos
administr
ivermectin
oral
mgkgsingledos
administr
fast
stercorali
japan
stercorali
distribut
nansei
island
chain
island
extend
southwestern
kyushu
northern
taiwan
young
person
newli
infect
stercorali
incid
infect
high
elderli
person
intern
stercorali
wide
distribut
tropicalsubtrop
area
domest
infect
also
japanes
travel
endem
area
possibl
infect
parasit
foreign
patient
endem
area
strongyloidiasi
alway
consid
patient
respiratori
symptom
andor
lung
lesion
eosinophilia
stercorali
percutan
infect
human
larva
penetr
human
skin
transfer
lung
blood
flow
larva
migrat
bronchi
trachea
epiglotti
esophagusstomach
reach
small
intestin
intestin
larva
develop
matur
adult
parasit
egg
deliv
adult
hatch
descend
intestin
tract
larva
excret
stool
larva
develop
infect
form
invadetransf
mucosa
around
anu
maintain
life
cycl
human
bodi
mode
infect
term
autoinfect
transfer
larva
lung
asthmaor
pneumonialik
symptom
transient
fever
cough
dyspnea
appear
indic
simpl
pulmonari
eosinophilia
relat
lumbricoid
duodenal
n
americanu
chest
xray
transient
nodularinfiltr
shadow
observ
mani
patient
show
peripher
blood
eosinophilia
andor
increas
total
ige
level
immunocompromis
patient
suppress
cellmedi
immun
atl
patient
hivaid
patient
receiv
immunosuppress
drug
number
stercorali
increas
acceler
autoinfect
larva
dissemin
variou
organ
lead
sever
condit
dissemin
strongyloidiasi
case
stridor
bloodi
sputum
tachypnea
proteinlos
gastroenter
ileu
mobil
exanthema
observ
furthermor
sever
pneumonia
relat
enter
bacteria
dissemin
larva
lung
abscess
bacteri
mening
concomitantli
occur
diagnosi
made
base
stercorali
larva
detect
stoolssputum
immunolog
diagnosi
also
use
drug
recommend
first
choic
dose
adult
children
ivermectin
oral
mgkgsingledos
administr
fast
addit
administr
dose
week
ai
repeat
administr
must
consid
case
dissemin
strongyloidiasi
studi
report
transrect
percutan
administr
use
patient
oral
administr
difficult
due
digest
symptom
second
choic
dose
adult
children
albendazol
oral
mgtwice
day
day
bi
cani
cati
infect
human
occur
oral
ingest
embryon
egg
cani
cati
also
occur
consumpt
beefchicken
liver
meat
contamin
larva
raw
insuffici
heat
food
consid
domin
rout
infect
japan
human
definit
host
cani
cati
becom
adult
human
bodi
larva
invad
human
bodi
transfer
variou
organ
blood
flow
intestin
mucosa
target
organ
lung
liver
eye
central
nervou
system
includ
spinal
cord
toxocariasi
typic
larva
migran
lesion
often
observ
lungliv
viscer
larva
migran
symptom
nonspecif
symptom
present
mani
case
diagnosi
made
base
peripher
blood
eosinophilia
multipl
nodular
shadow
lung
liver
ct
ocular
central
nervou
symptom
appear
patient
imposs
make
diagnosi
stool
examin
due
larva
migran
immunolog
diagnosi
use
definit
diagnosi
made
treatment
start
viscer
larva
migran
asymptomat
followup
may
continu
drug
recommend
first
choic
dose
adult
children
albendazol
oral
time
day
week
biii
drug
taken
meal
day
period
discontinu
establish
restart
drug
requir
second
choic
dose
adult
children
albendazol
oral
mgtwice
day
day
biii
mebendazol
oral
mgtwice
day
day
ciii
w
bancrofti
b
malayi
w
bancrofti
b
malayi
call
lymphat
filaria
infect
occur
parasit
transmit
human
mosquito
pathogenesi
lymphat
filariasi
relat
structur
function
abnorm
lymphat
channel
induc
parasit
adult
worm
infect
w
bancrofti
character
febril
attack
lymphedemaelephantiasi
hydrocel
chyluria
patient
infect
b
malayi
neither
hydrocel
chyluria
observ
lymphedema
lower
limb
elephantiasi
local
lower
thigh
microfilaria
produc
adult
worm
pathogen
rare
induc
allerg
reaction
lung
contribut
tropic
pulmonari
eosinophilia
tpe
condit
show
chronic
cours
differ
simpl
pulmonari
eosinophilia
cough
dyspnea
stridor
exacerb
night
observ
fever
malais
weight
loss
note
patient
chest
xray
bilater
reticular
nodular
lesion
detect
peripher
blood
eosinophilia
increas
antifilaria
antibodi
titer
observ
case
tpe
microfilaria
detect
treatment
perform
condit
may
gradual
exacerb
import
adequ
make
diagnosi
differenti
diseas
world
person
infect
lymphat
filaria
tpe
occur
less
risk
diseas
travel
unclear
patient
consist
foreign
person
endem
area
drug
recommend
first
choic
dose
adult
children
diethylcarbamazin
time
day
day
case
malayan
filariasi
mark
side
effect
digest
symptom
fever
lymphang
lymphaden
orchitisepididym
may
appear
therefor
half
dose
mgkg
administ
time
day
day
immiti
immiti
parasit
dog
right
ventricl
pulmonari
arteri
matur
femal
worm
produc
microfilaria
circul
peripher
blood
infect
human
mediat
microfilariaingest
mosquito
immiti
larva
human
subcutan
tissu
insert
mosquito
bite
larva
migrat
heart
die
dead
worm
produc
infarct
lodg
pulmonari
vessel
symptom
patient
symptom
thorac
pain
cough
bloodi
sputum
stridor
fever
report
typic
chest
xray
find
includ
solitari
coin
lesion
mani
case
abnorm
shadow
chest
xray
indic
health
checkup
immiti
infect
patholog
diagnos
tissu
specimen
extirp
tent
diagnosi
lung
cancer
point
peripher
blood
eosinophilia
rare
observ
drug
recommend
dose
adult
children
diagnosi
made
use
patholog
specimen
mani
patient
oral
treatment
necessari
necessari
diethylcarbamazin
mgkg
oral
administ
time
day
day
precaut
drug
japanes
packag
insert
describ
drug
mgkgday
oral
administ
twice
day
day
treatment
paragominiasi
howev
recommend
administr
mgkgday
time
day
day
base
refer
incid
side
effect
low
fever
abdomin
discomfort
nausea
diarrhea
headach
sometim
observ
